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ABSTRACT 
Breast cancer is a highly heterogeneous disease from the molecular and clinical point of 
view. Optimal treatment with the currently available drugs depends therefore on the ability to 
individually predict treatment. Presently available outcome prediction models are however 
suboptimal, single predictive variables have limited accuracy, and the actual clinical outcomes 
remain heterogeneous in any given prognostic group. ER status and HER-2 status are helpful in 
identifying patients who are not eligible for endocrine or trastuzumab therapies by virtue of their 
high negative predictive values (NPVs) and high sensitivities. However, only a minority of ER-
positive or HER-2-positive patients respond to receptor-targeted therapy. The positive predictive 
values (PPVs) of these tests are <50%. Moreover, currently there are no accepted molecular 
predictors of response to various chemotherapeutic drugs. These limitations have driven biomarker 
research to develop more accurate molecular predictors of clinical outcome. 
In the present thesis work we report data on an innovative strategy to predict treatment 
response to conventional therapies by combining in a hierarchical way genomic predictors related to 
prognosis and to treatment sensitivity and resistance. The strategy takes into account the intrinsic 
molecular heterogeneity of breast tumors by distinctly developing genomic predictors for each of 
the three main tumor subtypes defines as: ER+/Her2-, Her2+ and ER-/Her2-. The considered 
genomic predictors are built based on literature data and results previously obtained at the INT (as 
in the case of the prognostic role of ISG genes) and are treated as metagenes mainly to facilitate 
cross-platform comparisons and to stick to pathways with s clear biological role. An important part 
of the development of the prediction strategy deals with analytical approaches which were 
optimized to gain more accurate information from FFPE samples. 
 
Gene expression profiles used in such approach were obtained from public database, but 
also from expression studies carried out at INT on two types of samples; fresh frozen and formalin 
fixed samples. A detailed comparative analysis of technical solutions (Illumina HT 12, Illumina 
Ref8, Illumina DASL and Affymetrix HG Plus2.0 chips) for optimizing gene expression profiles in 
FFPE samples with heavily degraded and chemically-modified RNA is reported. A new robust 
protocol was developed based on linear amplification of RNA under conditions minimizing rRNA 
amplification, and on use of the Affymetrix HG Plus 2.0 chips. The protocol was tested in a pilot 
study on 60 samples to estimate the actual percentage of archived FFPE clinical samples which 
could yield technically acceptable gene expression profiles and to evaluate the biological reliability 
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of gene expression profiles obtained from fixed samples. Reliability was tested by comparing ER-
status classifiers developed using FF-derived expression data and testing the classifier on predicting 
ER status in FFPE and FF dataset. Prediction accuracy between the two types of samples was 
comparable (FF Cohen’s k 0,92, FFPE Cohen’s k 0.89). 
 
With the various tools developed as described above, it was possible to identify a priori in the 
ER+/Her2- a subset of patients who were predicted (and confirmed by external validation) to have 
95%  5-year disease free survival. Such accurate (and validated) prediction was achieved by 
combining optimized metagenes with clear biological roles in proliferation, ER signaling and 
immunity and separately analyzing prognostic and predictive information. 
Work is still in progress for the other molecular subtypes (Her2+ and ER-/Her2-). 
 
The role of immune genes was particularly interesting as it definitely added important information 
to refine prognosis in our strategy, but at the same way raised some questions due to its paradoxical 
role encompassing both tumor promotion and tumor inhibition. In our gene expression profiling 
data in node negative breast cancer patients, ISG expression was associated to likelihood to develop 
distant metastases in patients with ER+/Her2-tumors, but upon validation in larger data set it clearly 
emerged that the ISG prognostic role was strongly dependent on the molecular subtypes of the 
tumor (protective in patients with Her2+ tumors, risk-associated in patients with ER+/Her2- tumors, 
and neutral in those with ER-/Her2- tumors). Furthermore in the clinical setting a high ISG 
expression did not reflect stronger lymphocyte infiltration, and upon correction for genuine T cell 
associated genes ISG genes were found to be associated to proliferation. Interestingly in our clinical 
samples the ISG genes were demonstrated to be expressed by the cancer cells rather than the 
stroma. 
To further search for biological mechanism justifying the prognostic role of ISG expression we 
switched to in vitro co-cultures of epithelial cells with normal fibroblasts of different origin or 
CAFs.  Many different experimental setting either 2D or 3D were adopted and described in detail. 
The experimental setting played a major role on the experimental results. On the average basal-like 
cells were more sensitive to fibroblasts promoted effects in terms of cytokine secretion in the 
culture medium and up-regulation of ISG genes in the epithelial cells. Those cells were 
characterized by high intrinsic migratory and invasive ability which did not change much upon co-
cultures. 
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On the contrary luminal cells were stimulated to growth and gained invasive and migratory abilities 
after stimulation with fibroblasts and CAFs.  
Our experiments showed a complicated and sometimes controversial interplay between fibroblasts 
and epithelial cells which fully justifies the paradoxical role of the immune system in clinical 
tumors. 
 
In conclusion FFPE samples derived from clinical trials are non more an inaccessible source of 
biological and clinical information, and can be exploited to build true genomic predictor allowing a 
true personalized cancer treatment. While our prediction model proofed to be effective the role of 
immune genes and of stroma, although recognized as very important, is still elusive despite the 
development of different types of heterotypic cells co-culture models. 
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1. INTRODUCTION 
 
1.1 THE NORMAL BREAST 
 
To understand breast cancer, it helps to have some basic knowledge about its the normal structure. 
The structure of the female breast is complex, including fat and connective tissue, as well as lobes, 
lobules, ducts and lymph nodes.  
Each breast is made up mainly of lobules, that are milk-producing glands, ducts, tiny tubes that 
carry the milk from the lobules to the nipple, and stroma composed of fatty tissue and connective 
tissue surrounding the ducts and lobules, blood vessels, and lymphatic vessels (Fig 1a and 1b). 
  
Figures 1: a. mammary gland structure; b. enlargment of terminal mammary duct. 
 
Most breast cancers originate in the cells that line the ducts (ductal cancers), while same derive 
from the cells that line the lobules (lobular cancers). 
It is important to considerate the lymph system is important to understand because it is one way 
breast cancers can spread. This system has several parts. 
Lymph nodes are small, bean-shaped collections of immune system cells that are connected by 
lymphatic vessels. Lymph contains tissue fluid and waste products, as well as immune system cells. 
Breast cancer cells can enter lymphatic vessels and begin to grow in lymph nodes.  
Most lymphatic vessels in the breast connect to lymph nodes under the arm (axillary nodes). Some 
lymphatic vessels connect to lymph nodes inside the chest (internal mammary nodes) and those 
either above or below the collarbone (supraclavicular or infraclavicular nodes) (Fig.2). 
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Figure 2: tree mammary lymph nodes 
 
If the cancer cells have spread to lymph nodes, there is a higher chance that the cells could have 
also gotten into the bloodstream and spread (metastasized) to other sites in the body. The more 
lymph nodes contain breast cancer cells, the more likely it is that the cancer may be found in other 
organs as well. Because of this, the identification cancer cells in one or more lymph nodes impact 
on the treatment plan. Still, not all women with cancer cells in their lymph nodes develop 
metastases, and some women can have no cancer cells in their lymph nodes and later develop 
metastases. 
 
1.1.1 FACTORS INVOLVED IN MAMMARY GLAND DEVELOPMENT 
 
The mammary gland is a very dynamic tissue which undergoes dramatic changes during different 
developmental phases (1). In fact during puberty the mammary gland develops from a rudimentary 
tree to a branched epithelial network of ducts which can support alveolar development and 
subsequent milk production during pregnancy and lactation. All phases are under hormonal control: 
estrogen, progesterone and prolactin are the principal hormones that act on stromal cells to 
stimulate the branching process (2); estrogen and EGF, during puberty, control ductal elongation 
and branching; insulin growth factor (IGF), amphiregulin, neuregolin, (NRG) fibroblast growth 
factors (FGF) and receptors ERBB2 /3/4 are implicated in embryonic mammary gland development 
and branching morphogenesis; progesterone, prolactin and placental lactogens stimulate alveolar 
proliferation and differentiation during pregnancy. In addition to hormones, also the protease, as for 
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example the metalloproteases play a fundamental role in the branching process, these are both 
upstream and downstream of EGF receptor signaling by which they regulate growth factor function 
and branching. 
 
1.1.2 MAMMARY GLAND MORPHOLOGY AND PHYSIOLOGY 
 
1.1.2.1 Luminal and myoepithelial cells 
 
Quiescent mammary ducts are bilayered, one layer of luminal epithelial cells, surrounded by a layer 
of myoepithelial cells (also referred to as basal cells). Luminal and myoepithelial cells originate 
from the same progenitor cell. This common progenitor differentiates into a luminal progenitor and 
a myoepithelial progenitor cell that finally differentiates to a myoepithelial cell (3). Luminal 
progenitors can differentiate to mature ductal, alveolar or secretory cells. Luminal epithelial cells 
differentiate to milk-producing cells upon stimulation with prolactin. Breast cancers mainly arise in 
the luminal epithelial compartment (4). This is most likely related to the dynamics of differentiation 
and dedifferentiation of these cells. Myoepithelial cells function as a guardian of tissue integrity of 
the mammary gland by maintaining tissue polarity (5) (6). To distinguish luminal and myoepithelial 
cells several markers can be used. Luminal epithelial cells are MUC-1 positive and express 
cytokeratin 8 (CK8). Myoepithelial cells on the other hand are smooth muscle actin-1 (SMA-1) 
positive, express cytokeratin 5 (CK5) and p63. 
 
1.1.2.2 Basement membrane 
 
Epithelial cells are dependent on adhesion to other cells and to the extracellular matrix in order to 
survive. Also in the mammary gland the basement membrane has an important role as a survival 
factor for mammary epithelial cells. The mammary basement membrane contains collagen IV, and 
laminin-1 and -11, which are cross-linked by nidogen-1 and 2 to form a gel-like structure to which 
mammary epithelial cells adhere (7). The adhesion of mammary epithelial cells to extracellular 
matrix via integrins, family of heterodimeric transmembrane glycoprotein receptors, has been 
shown to suppress apoptosis (8;9). Integrins regulate cell shape and facilitate migration by 
providing a structural link with the actin cytoskeleton. Apart from integrins, several other receptors 
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such as dystroglycans, syndecans and galactosyl transferases function as adhesion receptors for 
basement membrane proteins (10). Binding of integrins to the ECM promotes the formation of 
adhesion complexes at the plasma membrane. These adhesion complexes are important for 
cytoskeleton assembly. The expression and deposition of extracellular matrix proteins is frequently 
altered in breast cancer. Reduced expression of integrins and lack of basement membrane is often 
observed in metastatic disease.  
 
1.1.2.3 Stroma e microenvironment 
 
Stromal cells secrete a separate set of extracellular components such as fibronectin (fn). The stroma 
of mammary gland consists of extracellular matrix (ECM) and a variety of mesenchymal cells, 
including fibroblast, myofibroblast, endothelial cells, pericytes and leukocytes (11). Stromal-
epithelial interactions play important roles during mammary gland development. Macrophages and 
eosinophils are recruited to the mammary gland simultaneous with the outgrowth of terminal end 
buds (TEBs). Macrophages are recruited mostly to the neck of the TEB while eosinophils are 
mainly located around the head of the TEB. 
Leukocyte depletion from the mammary gland was shown to result in dramatic inhibition of ductal 
development. Survival and proliferation of macrophages as well as macrophage behavior, 
morphology and motility is regulated by colony-stimulating factor-1 (CSF-1). Regulation of the 
CSF-1/CSF-1R system seems to be crucial for ductal outgrowth. Since the CSF-1 receptor (CSF-
1R) is exclusively expressed on macrophages in the mammary gland tissue, macrophages are 
important stromal factors in mammary gland development. 
The extracellular matrix (ECM) is a dominant regulator of tissue development and homeostasis, it 
regulates growth, differentiation and apoptosis in human mammary epithelial cells (MEC) through a 
hierarchy of transcriptional events involving the intricate interplay between soluble and physical 
signaling pathways. The study of Weaver et al. shown that this pathway are influenced by the tissue 
structure that is directed by the cooperative interactions of the cell-cell and cell-ECM and can by 
modified by stromal factors (12). 
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1.2 BREAST CANCER  
 
Breast cancer is the formation of a malignant tumor that has developed from cells in the breast. A 
malignant tumor is a group of cancer cells that may invade surrounding tissues or spread to distant 
areas of the body, thereby giving rise to metastases. Breast cancer affects predominantly women but 
may develop, in some cases, also in the men. 
 
1.2.1 EPIDEMIOLOGY 
 
Breast cancer is the most common cancer diagnosed in women and is the second most frequent 
cause of cancer mortality in western women. The past 20 year have seen a significant reduction in 
breast cancer-related mortality, largely due to improved early detection and the development of 
more effective adjuvant therapies. According to the current statistics of the AIRC (Associazione 
Italiana per la Ricerca sul Cancro), breast cancer accounts for 25% of all female cancers is 
responsible for 17% of cancer death in women in Italy and it is estimates that about 1 in 10 women 
will develop breast cancer during her lifetime. In Italy 37000 new cases are diagnosed each year, 
152 per 100 000 women. 
 
1.2.2 RISK FACTORS 
 
Risk factors associated with the development of the tumor can be classified as lifestyle dependent or 
independent. 
Every woman is at risk for developing breast cancer. Several relatively strong risk factors for breast 
cancer that affect large proportions of the general population have been known for some time. 
However, the vast majority of breast cancer cases occur in women who have no identifiable risk 
factors other than their gender (13). The “established” risk factors for breast cancer are female 
gender, age, previous breast cancer, benign breast disease, hereditary factors (family history of 
breast cancer), early age at menarche, late age at menopause, late age at first full-term pregnancy, 
postmenopausal obesity, low physical activity, race/ethnicity and high-dose exposure to ionizing 
radiation early in life. 
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Other putative risk factors for breast cancer include never having been pregnant, having only one 
pregnancy rather than many, not breast feeding after pregnancy, use of postmenopausal estrogen 
replacement therapy or postmenopausal hormone (estrogen/progestin) replacement therapy, use of 
oral contraceptives, certain specific dietary styles (high intake of fat and low intakes of fiber, fruits, 
and vegetables, low intake of phytoestrogens), alcohol consumption, tobacco smoking, and 
abortion. Although men develop breast cancer, the disease is 100 times more likely to occur in a 
woman than in a man (14).Women are at a higher risk of breast cancer because they have much 
more breast tissue than men do, and are more exposed during their life to estrogen stimulation. 
Breast cancer affects women of all races and nationalities, and the incidence globally shows an 
increase in industrialized countries or in those with a recent industrialization (15). 
However, most of the women who get breast cancer (approximately 80%) do not have a strong 
family history of disease (16). The effect of family history on breast cancer risk is believed to be 
due primarily to genetic factors. As much as 5-10% of all breast cancer cases are attributable to 
specific inherited single-gene mutation, and many other cases have some genetic component. 
Epidemiological studies have shown that in women with a family history of breast cancer, the risk 
is increased two- to three fold. 
Hereditary mutations of the BRCA1 and BRCA2 genes are responsible for 5% of all breast cancers. 
These genes are located on chromosome 17q21 and 13q13 respectively, and are involved in 
processes for cell survival, as the repair of breaks in DNA double helix, and through the formation 
of multiprotein complexes, remodeling and transcription of the DNA, thanks to the link with the 
RNA polymerase II RNA, helicase A, the histone-deacetylases (HDACs) and other proteins. 
BRCA1 that BRCA2 are also involved in maintaining the structural integrity of chromosomes and 
in the apoptotic process (17). 
The diagnosis of breast cancer, especially in young women, is associated with the risk development  
of tumor in controlateral gland: in women who develop invasive cancer in the left breast within 30 
years of life, the probability of a similar development in the right breast within in 40 years of age is 
5% (0.5% per year). In addition, the likelihood of developing a primary tumor in the breast, 
increases proportionally with age, but the risk of controlateral breast cancer is reduced during the 
course of life. Several hypotheses have been put to explain these observations, although no one 
seems to give a full explanation (18). Additional risk factors are: early menarche (12 old or 
younger), late menopausal (55 or older>) and age-related factors in the first pregnancy. These are 
believed to me mediated through estrogen production (5). 
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An increased risk of breast cancer can be due to long-term exposure to estrogen and progesterone in 
women with early menarche and late menopause, or the use of long-term hormones therapy or 
contraceptives. Age at first pregnancy is another aspect of reproductive history that is associated 
with breast cancer risk. Women who have their first full-term pregnancy at a relatively early age 
have a lower risk of breast cancer than those who never have children or those who have their first 
child relatively late in life (19). To wait a long time between multiple pregnancies, miscarriages or 
abortion, twin births at first pregnancy with hypertension during this period (20) are other risk 
factors.  
In addition there are several risk factors depending to lifestyle but is important to emphasize that the 
risk can be drastically reduced by the behavior of each person. A rich animal fats diet, but low fruits 
and vegetables is associated with an increase in the frequency of breast cancer, so different eating 
habits in different countries are therefore closely linked to the frequency of occurrence of the 
disease. 
The metabolic syndrome is associated with an increased risk of breast cancer. Obese women in fact, 
with a biomass index > 40 kg/m2, show a greater susceptibility to cancer; the obesity cause 20% of 
deaths (21). These subjects has been shown not only a greater risk development of breast cancer, 
but also an increased risk of distant metastases (22;23). 
Such observations are supported by the evidence of difference amount of circulating hormones, like 
estrogen and insulin, in obese person with respect to normal-weight person. Recently it has been 
shown how the adipocytes in the mammary gland through the secretion of cytokines can influence 
the proliferation and tumor invasion. (24)(25). 
An association between risk of breast cancer and excessive body mass was found in 
postmenopausal women, indeed. Before menopause the ovaries produce most of the estrogens and 
the adipose tissue produces only a small amount, after menopause, most of estrogen are produced 
from periferic aromatization in fat. 
However, the connection between obesity and breast cancer seems to be more complicated than 
described, the risk is increased for women who became obese in adulthood, while it may not 
increase in obese women after birth. In addition, an excess of fat in the abdominal circumference 
has a greater effect on risk than the same amount of fat in the area of the hips and thighs (26). 
Alcohol consumption was defined as a risk factor for the development of breast cancer: the risk 
increases is dose-dependent with the drink. A drink consumed daily (12once-5once of beer or wine) 
increases this parameter by 10%, two drinks consumed daily increases the risk to 20% (27). The 
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consumption of alcohol not only increases the risk of developing the disease but also the risk of 
relapses and deaths for breast cancer. The hypothesis proposed to explain how alcohol may induce 
this process are related to the increase in reactive oxygen species and acetaldehyde, and to hormonal 
(estrogen and insulin-like growth factor 1 (IGF-1 )) pathways variation. These hypotheses however 
have not been confirmed (28-30). 
Breast cancer is increasingly being diagnosed in Caucasian post-menopausal women or women 
born in the countries of northern Europe or America. A common denominator for the risk of 
developing breast cancer is related to the reproductive history. Numerous studies have shown that 
early pregnancies decrease the risk of developing breast cancer after 50 years of age, while a higher 
frequency of breast cancer is instead observed in nulliparous women between 30 and 34 years of 
age. The nulliparity can then be seen as a risk factor for the development of breast cancer while 
pregnancy would play a protective action in mammary epithelial level (15). 
 
1.2.3 HISTOTYPES 
 
Breast cancers are derived from the epithelial cells that line the terminal duct lobular unit. Cancer 
cells that remain within the basement membrane of the elements of the terminal duct lobular unit 
and the draining duct are classified as in situ or non invasive. In invasive breast cancer there is 
instead a dissemination of cancer cells outside the basement membrane of the ducts and lobules into 
the surrounding adjacent normal tissue. Both in situ and invasive cancers have characteristic 
patterns by which they can be classified. 
Invasive breast cancers are divide into ductal carcinoma (DC) and lobular (LC). 
Most carcinomas occurs in the duct lobular terminal units (UTDL) and subsequently, for 
mechanisms still not well known, gives rise to different tumors, not only for their morphology, but 
also for the biological behavior. Both types of tumors (DC and LC) can be in situ (remain confined 
in tissue in which it develops) or infiltrating. The ductal carcinoma accounts for about 75% of 
infiltrating tumors, while the lobular about 5%. Less frequent histotypes infiltrating are: medullary 
carcinoma (15%), colloid or mucinous (2%), tubular (1-2%), and other rare forms. The transition 
from normal structures to carcinoma in situ takes place through the formation of intermediate 
lesions, different for the two main types of tumor, called pre-neoplastic lesions. 
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1.2.4 STAGING AND CLASSIFICATION OF BREAST CANCER 
 
Staging describes the severity of a person’s cancer based on the extent of the original (primary) 
tumor and whether or not cancer has spread in the body. Staging is important for several reasons: 
 Staging helps the physician to plan the appropriate treatment. 
 The stage can be used to estimate the person’s prognosis. 
 Knowing the stage is important in identifying clinical trials that may be suitable for a 
particular patient. 
 Staging helps health care providers and researchers exchange information about 
patients; it also gives them a common terminology for evaluating the results of 
clinical trials and comparing the results of different trials. 
Staging is based on knowledge of the way cancer progresses.  
The TNM system is one of the most widely used staging systems. This has been accepted by the 
International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC).  
The TNM system is based on the extent of the tumor (T), the extent of spread to the lymph nodes 
(N), and the presence of distant metastasis (M). A number is added to each letter to indicate the size 
or extent of the primary tumor and the extent of cancer spread (Tab.1). 
 'T' can be 1, 2, 3 or 4, with 1 being small and 4 large. 
 'N' can be between 0 (no positive nodes) and 3 (many of positive nodes). 
 'M' can either be 0 (the cancer hasn't spread) or 1 (the cancer has spread). 
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Primary Tumor (T)  
TX Primary tumor cannot be evaluated 
T0 No evidence of primary tumor 
Tis Carcinoma in situ (CIS; abnormal cells are present but have not 
spread to neighboring tissue; although not cancer, CIS may 
become cancer and is sometimes called preinvasive cancer) 
T1, T2, T3, T4 Size and/or extent of the primary tumor 
Regional Lymph Nodes (N)  
NX Regional lymph nodes cannot be evaluated 
N0 No regional lymph node involvement 
N1, N2, N3 Involvement of regional lymph nodes (number of lymph nodes and/or extent of spread) 
Distant Metastasis (M)  
MX Distant metastasis cannot be evaluated 
M0 No distant metastasis 
M1 Distant metastasis is present 
Table 1: TNM classification system. 
The breast cancer stage is based on the results of testing that is done on the tumor and lymph nodes 
removed during surgery and other tests. For many cancers, TNM combinations correspond to one of 
five stages. 
Stage 0 (carcinoma in situ) 
There are 3 types of breast carcinoma in situ: 
 Ductal carcinoma in situ (DCIS) is a noninvasive condition in which abnormal cells are 
found in the lining of a breast duct. The abnormal cells have not spread outside the duct to 
other tissues in the breast. In some cases, DCIS may become invasive cancer and spread to 
other tissues. At this time, there is no way to know which lesions could become invasive 
(Fig.3). 
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Figure 3: Ductal Carcinoma In Situ (DCIS) 
 
 Lobular carcinoma in situ (LCIS) is a condition in which abnormal cells are found in the 
lobules of the breast. This condition seldom becomes invasive cancer. However, having 
LCIS in one breast increases the risk of developing breast cancer in either breast.  
 Paget disease of the nipple is a condition in which abnormal cells are found in the nipple 
only.  
 
Figure 4: Lobular Carcinoma In Situ (LCIS) 
Stage I 
 In stage I, cancer has formed. Stage I is divided into stages IA and IB. 
 In stage IA (Fig. 1a), the tumor is 2 centimeters or smaller. Cancer has not spread outside 
the breast. 
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 In stage IB (Fig. 1b), small clusters of breast cancer cells (larger than 0.2 millimeter but not 
larger than 2 millimeters) are found in the lymph nodes and either: 
 no tumor is found in the breast; or 
 the tumor is 2 centimeters or smaller. 
 
 
Figures 5: a. Stage IA breast cancer; b. Stage IB breast cancer. 
Stage II 
Stage II is divided into stages IIA and IIB. 
In stage IIA: 
 no tumor is found in the breast or the tumor is 2 centimeters or smaller. Cancer (larger than 
2 millimeters) is found in 1 to 3 axillary lymph nodes or in the lymph nodes near the 
breastbone (found during a sentinel lymph node biopsy); or 
 the tumor is larger than 2 centimeters but not larger than 5 centimeters. Cancer has not 
spread to the lymph nodes (Fig.6). 
 
Figure 6: stage IIA breast cancer 
a b 
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In stage IIB (Fig.7), the tumor is: 
 larger than 2 centimeters but not larger than 5 centimeters. Small clusters of 
breast cancer cells (larger than 0.2 millimeter but not larger than 2 millimeters) 
are found in the lymph nodes; or 
 larger than 2 centimeters but not larger than 5 centimeters. Cancer has spread to 
1 to 3 axillary lymph nodes or to the lymph nodes near the breastbone (found 
during a sentinel lymph node biopsy); or 
 larger than 5 centimeters. Cancer has not spread to the lymph nodes. 
 
Figure 7: stage IIB breast cancer 
 
 
Stage IIIA  
In stage IIIA: 
 no tumor is found in the breast or the tumor may be any size. Cancer is found in 4 to 9 
axillary lymph nodes or in the lymph nodes near the breastbone (found during imaging tests 
or a physical exam); or 
 the tumor is larger than 5 centimeters. Small clusters of breast cancer cells (larger than 0.2 
millimeter but not larger than 2 millimeters) are found in the lymph nodes; or 
 the tumor is larger than 5 centimeters. Cancer has spread to 1 to 3 axillary lymph nodes or to 
the lymph nodes near the breastbone (found during a sentinel lymph node biopsy) (Fig.8). 
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Figure 8: stage IIIA breast cancer 
 
Stage IIIB  
In stage IIIB (Fig.9), the tumor may be any size and cancer has spread to the chest wall and/or to the 
skin of the breast and caused swelling or an ulcer. Also, cancer may have spread to: 
 up to 9 axillary lymph nodes; or 
 the lymph nodes near the breastbone. 
Cancer that has spread to the skin of the breast may also be inflammatory breast cancer.  
 
Figure 9: stage IIIB breast cancer 
 
Stage IIIC 
 In stage IIIC, no tumor is found in the breast or the tumor may be any size. Cancer may have 
spread to the skin of the breast and caused swelling or an ulcer and/or has spread to the chest wall. 
Also, cancer has spread to: 
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 10 or more axillary lymph nodes; or 
 lymph nodes above or below the collarbone; or 
 axillary lymph nodes and lymph nodes near the breastbone. 
Cancer that has spread to the skin of the breast may also be inflammatory breast cancer. For 
treatment, stage IIIC breast cancer is divided into operable and inoperable stage IIIC (Fig.10). 
 
Figure 10: stage IIIC breast cancer 
 
Stage IV  
 
Stage IV breast cancer. The cancer has spread to other parts of the body, most often the bones, 
lungs, liver, or brain.  
In stage IV, cancer has spread to other organs of the body, most often the bones, lungs, liver, or 
brain (Fig.11). 
 
Figure 11: stage IV breast cancer 
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1.3 BREAST CANCER TREATMENT 
 
Different types of treatment are available for patients with breast cancer. Some are standard (the 
currently used treatment), and some are being tested in clinical trials.  
Most patients with breast cancer have surgery to remove the cancer from the breast. Some of the 
lymph nodes under the arm are usually taken out and looked at under a microscope to see if they 
contain cancer cells. 
Breast-conserving surgery is an operation to remove the cancer but not the breast itself, includes the 
following: 
 Lumpectomy: that is surgery to remove a tumor (lump) and a small amount of normal tissue 
around it. 
 Partial mastectomy:  to remove the part of the breast that has cancer and some normal tissue 
around it. The lining over the chest muscles below the cancer may also be removed. This 
procedure is also called a segmental mastectomy. 
Patients who are treated with breast-conserving surgery may also have some of the lymph nodes 
under the arm removed for biopsy. This procedure is called lymph node dissection. Other types of 
surgery include the following: 
 Total mastectomy: surgery to remove the whole breast that has cancer. This procedure is 
also called a simple mastectomy. Some of the lymph nodes under the arm may be removed 
for biopsy at the same time as the breast surgery or after. This is done through a separate 
incision.  
 Modified radical mastectomy: surgery to remove the whole breast that has cancer, many of 
the lymph nodes under the arm, the lining over the chest muscles, and sometimes, part of the 
chest wall muscles.  
Other treatment used for breast cancer is chemotherapy that may be given also before surgery to 
remove the tumor. In this case, chemotherapy will shrink the tumor and reduce the amount of tissue 
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that needs to be removed during surgery. Treatment given before surgery is called neoadjuvant 
therapy. 
Even if the physician removes all the cancer that can be seen at the time of the surgery, some 
patients may be given radiation therapy, chemotherapy, or hormone therapy after surgery to kill any 
cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will 
come back, is called adjuvant therapy. 
Sentinel lymph node biopsy is the removal of the sentinel lymph node during surgery. The sentinel 
lymph node is the first lymph node to receive lymphatic drainage from a tumor. It is the first lymph 
node where cancer cells are likely to spread to from the tumor. A radioactive substance and/or blue 
dye is injected near the tumor. The substance or dye flows through the lymph ducts to the lymph 
nodes. The first lymph node to receive the substance or dye is removed. A pathologist views the 
tissue under a microscope to look for cancer cells. If cancer cells are not found, it may not be 
necessary to remove more lymph nodes. After the sentinel lymph node biopsy, the surgeon removes 
the tumor (breast-conserving surgery or mastectomy). 
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to 
kill cancer cells or keep them from growing. There are two types of radiation therapy: external 
radiation therapy uses a machine outside the body to send radiation toward the cancer, and internal 
radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are 
placed directly into or near the cancer. The way the radiation therapy is given depends on the type 
and stage of the cancer being treated. 
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by 
killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or 
injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells 
throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the 
cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer 
cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the 
type and stage of the cancer being treated. 
Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops 
cancer cells from growing. It is the first described target therapy for breast cancer and is effective 
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only for estrogen receptor positive (ER positive) cancers. A better treatment response rate is 
observed in patients with ER+ tumors which also express the progesterone receptor (PgR). 
Hormone therapy can be used after surgery or other treatments to decrease the chance of recurrence. 
If the cancer has already spread, hormone therapy may shrink and control it.  
Treatments that can be used in hormone therapy include:  
 Medications that block hormones from stimulating cancer cells. Tamoxifen is the most 
commonly used selective estrogen receptor modulator (SERM). SERMs act by blocking 
estrogen from attaching to the estrogen receptor on the cancer cells, slowing the growth of 
tumors and killing tumor cells. Tamoxifen can be used in both pre- and postmenopausal 
women. Possible side effects include fatigue, hot flashes, night sweats and vaginal dryness. 
More significant risks include cataracts, blood clots, stroke and uterine cancer. 
 Medications that stop estrogen synthesis in peripheral tissues after menopause. One 
group of drugs called aromatase inhibitors blocks the action of an enzyme that converts 
androgens in the body into estrogen. These drugs are effective only in postmenopausal 
women. Aromatase inhibitors include anastrozole (Arimidex), letrozole (Femara) and 
exemestane (Aromasin). Side effects of aromatase inhibitors include joint and muscle pain, 
as well as an increased risk of bone thinning (osteoporosis). Another drug, fulvestrant 
(Faslodex), directly blocks estrogen, which keeps tumors from getting the estrogen they 
need to survive. Fulvestrant is generally used in postmenopausal women for whom other 
hormone-blocking therapy is not effective or who cannot take tamoxifen. Side effects that 
may occur include fatigue, nausea and hot flashes. Fulvestrant is given by injection once a 
month. 
 Surgery or medications to stop hormone production in the ovaries. In premenopausal 
women, surgery to remove the ovaries or medications to stop the ovaries from making 
estrogen can be an effective hormonal treatment. This type of surgery is known as 
prophylactic phorectomy and may be called surgical menopause. 
For the treatment of early stage breast cancer, certain aromatase inhibitors may be used as adjuvant 
therapy instead of tamoxifen or after 2 or more years of tamoxifen. For the treatment of metastatic 
breast cancer, aromatase inhibitors are being tested in clinical trials to compare them to hormone 
therapy with tamoxifen. 
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Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack 
specific cancer cells without harming normal cells. Monoclonal antibodies and tyrosine kinase 
inhibitors are two types of targeted therapies used in the treatment of breast cancer. PARP inhibitors 
are a type of targeted therapy being studied for the treatment of triple-negative breast cancer. 
Tyrosine kinase inhibitors are targeted therapy drugs that block signals needed for tumors to grow. 
Tyrosine kinase inhibitors may be used with other anticancer drugs as adjuvant therapy.  
 
Monoclonal antibody therapy is a cancer treatment that uses antibodies made in the laboratory, from 
a single type of immune system cell. These antibodies can identify substances on cancer cells or 
normal substances that may help cancer cells grow. The antibodies attach to the substances and kill 
the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given 
by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to 
cancer cells. Monoclonal antibodies may be used in combination with chemotherapy as adjuvant 
therapy. 
 Trastuzumab (Herceptin). Some breast cancers contain excessive amounts of a protein 
called human growth factor receptor 2 (HER2). Trastuzumab targets this protein that is 
directly involved in breast cancer cells growth and survival. Side effects may include heart 
damage, headaches and skin rashes. About one-fourth of patients with breast cancer have 
tumors that may be treated with trastuzumab combined with chemotherapy. 
 Pertuzumab is a monoclonal antibody that may be combined with trastuzumab and 
chemotherapy to treat breast cancer. It may be used to treat certain patients with HER2-
positive breast cancer that has metastasized . 
 Lapatinib (Tykerb). Lapatinib targets the HER2 protein and is approved for use in 
advanced metastatic breast cancer. Lapatinib is generally used for women who have already 
tried trastuzumab and their cancer has progressed. Potential side effects include nausea, 
vomiting, diarrhea, fatigue, mouth sores, skin rashes, and painful hands and feet. 
 Bevacizumab (Avastin). Bevacizumab is a drug designed to interfere with VEGF-promoted 
neoangiogenesis. Without new blood vessels to bring oxygen and nutrients to the tumor, the 
cancer cells die. Possible side effects include fatigue, high blood pressure, mouth sores, 
headaches, slow wound healing, blood clots, heart damage, kidney damage, high blood 
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pressure and congestive heart failure. Recent data suggests that although this medication 
may help slow the growth of breast cancer, it does not appear to increase survival times 
probably due to induction of hypoxia-mediated tumor-promoting effects. Use of 
bevacizumab in breast cancer therefore still controversial.  
Clinical trials  
Clinical trials are used to test new and promising agents in the treatment of cancer. Clinical trials 
represent the cutting edge of cancer treatment, but they are by definition the administration of 
unproven treatments that may or may not be superior to currently available therapies.  
Examples of treatments being studied in breast cancer clinical trials include:  
 New combinations of existing drugs. Researchers are studying new ways of combining 
existing chemotherapy, hormone therapy and targeted-therapy drugs. Testing new 
combinations may help determine if certain breast cancers are more susceptible to specific 
combinations. 
 Bone-building drugs to prevent breast cancer recurrence. Previous research found that 
adding a bone-building drug to hormone therapy treatment after surgery for premenopausal 
women reduced the risk of breast cancer recurrence. The drug used in the study, zoledronic 
acid (Reclast, Zometa), is a type of drug called a bisphosphonate that is used to treat 
osteoporosis and other bone diseases.  
 Using higher doses of radiation over a shorter period of time on a smaller portion of 
the breast. Researchers are studying partial breast irradiation in women who have 
undergone lumpectomy. Partial breast irradiation involves higher doses of radiation aimed at 
only a portion of the breast, rather than the entire breast 
 
 
1.4 ROLE OF BIOMARKERS  
 
The TNM system, 50 years after its introduction, is still the main staging system to define the initial 
clinical aggressiveness of the tumor and consequently to modulate the treatment.  
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However, over the years, the identification of specific molecular alterations in tumor cells directly 
responsible and/or associated with transformation and tumor progression, has suggested the 
possibility of integrating the TNM anatomic staging with a bio- functional tumor characteristics. 
A significant number of potential biomarkers of clinical utility were identified thanks to the 
increasing knowledge of tumor biology and to the availability of high-throughput technologies. 
Nevertheless, the real clinical utility of most of the biomarkers is still very controversial. 
It is in fact important to know if therapeutic decisions guided by prediction based on biomarkers 
will add a direct benefit to the patient compared decisions taken based on conventional clinical 
pathological factors. Direct benefit means a better control of the tumor, a better therapeutic ratio 
linked to a reduction of the side effects or even the non-prescription of an ineffective treatment.  
The National Cancer Institute (NCI) definition of biomarker is: “A biological molecule found in 
blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition 
or disease. A biomarker may be used to see how well the body responds to a treatment for a disease 
or condition. Also called molecular marker and signature molecule."  
It is necessary to distinguish between disease-related and drug-related biomarkers. Disease-related 
biomarkers give an indication of the probable effect of treatment on patient (risk indicator or 
predictive biomarkers), if a disease already exists (diagnostic biomarker), or how such a disease 
may develop in an individual case regardless of the type of treatment (prognostic biomarker). 
Predictive biomarkers help to assess the most likely response to a particular treatment type, while 
prognostic markers show the progression of disease with or without treatment (31). In contrast, 
drug-related biomarkers indicate whether a drug will be effective in a specific patient and how the 
patient’s body will process it. 
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Figure 12: Biomarkers types 
 
Prognostic  
    These cancer biomarkers help to assess the risk of developing a particular cancer and determine 
prognosis. They provide information to identify patients with different probabilities of survival or 
recovery of the disease, or tumors with highly invasive phenotype. In breast cancer patients with 
axillary lymph node metastases are considered at risk of relapse and therefore subjected to adjuvant 
treatments after surgical removal of the primary tumor. For patients that at the time of surgery do 
not have evidence of lymph node metastases, the decision is more difficult because a significant 
proportion will not experience a recurrence, while in about 30% of cases distant site disease will 
develop which will not be controlled by simple surgical eradication of the primary tumor. In such a 
situation the use of a biomarker is very useful. 
Diagnostic 
    Diagnostic markers guide the diagnosis in particular type of cancers when pathologists are unable 
to identify the specific type of cancer based on morphology only. 
Predictive 
    Predictive biomarkers predict the response to cancer drug(s) or treatment(s) in the patient (32). 
An example is given by the human epidermal growth factor receptor 2 (HER-2) overexpression due 
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to amplification of the HER-2 gene. Breast cancer patients with this abnormal increase of HER-2 
respond to trastuzumab (Herceptin®). However, breast cancer patients only over-expressing HER-2 
protein without gene amplification are not recommended to be treated with this drug. In breast 
cancer, the presence of receptors for estrogen (ER) and progesterone (PgR) is the strongest 
predictor of response to a hormone treatment with anti-estrogen (tamoxifen) or with aromatase 
inhibitor. 
Pharmacodynamics and Pharmacokinetics 
    Cancer biomarkers under this category help determine the most effective dosage of drug or 
therapy is needed for that specific person (33). These biomarkers are just another tool aiding the 
field of personalized medicine.  
Recurrence 
    Recurrence biomarkers are used to predict if cancer is likely to recur after treatment. An example 
is the Oncotype DX® breast cancer assay. This assay measures the expression of several genes 
within a breast tumor sample and allows to calculate a score (recurrence score, RR) associated to 
the likelihood of the patient to experience a relapse that the patient’s cancer will return. 
The sensitivity (ability to detect all positive cases) and specificity (ability to avoid false positives) 
of cancer biomarker determine its reliability. In addition to being reliable, provide a proved clinical 
benefit, a new biomarker must also provide independent and non-redundant information with 
respect to that provided by other markers/classifiers. The biomarker assay must be easily accessible 
to allow the widest possible clinical application and its determination must be standardized and 
reproducible. Finally, the optimal cancer biomarker is one that can be assessed on easily accessed 
biosamples (i.e. blood, urine, tissue from biopsy). 
    For breast cancer many markers based on gene expression signatures have been described, but 
only a few have been approved for clinical use in specific settings by the Food and Drug 
Administration (FDA). 
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1.5 TUMOR MICROENVIRONMENT 
 
The tumor microenvironment composed of non cancer cells (immune cells and stromal cells) and 
extracellular matrix has been increasingly recognized as a major factor influencing the growth of 
cancer. It is not a simple bystander, but plays an important role in determining tumor progression 
and response to treatment (34). 
While the normal cellular microenvironment con inhibit malignant cell growth, the modification 
that occur in the tumor microenvironment synergistically support cell proliferation. A variety of 
stromal cells in the surrounding environment are recruited by tumours, and these not only enhance 
growth of the primary cancer but also facilitate its metastatic dissemination to distant organs. 
Tumor epithelial cells are surrounded by the tumor microenvironment, which is composed of the 
extracellular matrix (ECM) and various other cell types, such as endothelial cells, fibroblast, 
myofibroblast, leukocytes and myoepithelial and endothelial cells, that play a role in the initiation 
and progression of neoplasms (35;36). Cross-talk between epithelial and stromal cells is known to 
be essential for differentiation and development of normal organs and tissue as well as for the 
growth and progression of tumours.  
Several studies have provided insight on the molecular characteristics differentiating tumor-
associated stroma from normal stroma. Allinen and colleagues suggested that during cancer 
progression, striking changes in gene expression occurred in almost every cell type, with the most 
dramatic and consistent change (other than in the malignant epithelial cells) detected in cells 
expressing the surface marker CD10, which encompasse myoepithelial cells and myofibroblast 
(37). 
Often in invasive carcinoma there is an expansion of tumor stroma, which is morphologically 
identified as desmoplasia, an area where tumor and stroma actively interact (38).  
Fibroblast, among stromal cells, are the major cellular component, and have a profound influence 
on the phenotype of various carcinomas, inducing the production of various growth factors and 
chemokines and their release into the in the microenvironmental (39;40). 
Stromal and other non-malignant cells create a supportive microenvironment for tumor growth, 
angiogenesis, and metastasis (40).. The tumor recruits endothelial cells, fibroblasts, and 
inflammatory cells, pericytes, and these cells and the components of the extracellular matrix (ECM) 
secreted by them contribute to the microenvironment composition. Stromal cells generate both 
tumor enhancing and tumor suppressing signals. Fibroblast isolated from carcinoma, named 
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carcinoma-associated fibroblast (CAF), show biological function distinct from  those of normal 
fibroblast in tumor progression and angiogenesis (41). Cancer-associated fibroblasts (CAF) and 
myofibroblasts are abnormal stromal cells, but not malignant, and promote angiogenesis and 
proliferation. These fibroblasts secrete growth factors and cytokines that produce oncogenic signals. 
In a comparative study which isolated both CAF and normal fibroblasts from six patients with 
invasive breast cancer, Orimo, et al., demonstrated that CAF were able to promote tumor growth 
more than normal fibroblasts (41). These activated fibroblasts were able to promote angiogenesis 
via expression of stromal cell-derived factor-1 (SDF-1 or CXCL12). SDF-1 produces an endocrine 
effect by recruiting circulating endothelial progenitor cells (EPC) to the tumor. Tumor cells also 
contain CXCR4, the receptor for SDF-1, so stromal SDF-1 is able to directly stimulate tumor 
growth through a paracrine effect. The EPC recruited to the tumor by the cancer-associated 
fibroblasts are capable of being differentiated into tumor-associated vascular endothelial cells and 
used to construct new capillaries (41). Circulating EPC migrate to other tissues and form a 
“premetastatic niche” for the colonization of circulating tumor cells (42). SDF-1 is not the only 
factor that participates in recruiting cells to the tumor microenvironment. Growth factors secreted 
by the tumor also control the composition of the microenvironment. Transforming growth factor-β 
(TGF-β) recruits EPC to the microenvironment and is involved in activation of fibroblasts to CAF, 
while platelet derived growth factor (PDGF) is involved in recruiting fibroblasts and inducing their 
proliferation. VEGF does not directly recruit fibroblasts, but indirectly supports 
microenvironmental changes via creation of dysfunctional vascularization that allows plasma 
leakage, which attracts fibroblasts and other cells (42) .The microenvironment may convert 
recruited stromal cells to cancer-associated cells through epigenetic changes, including DNA 
methylation and chromatin remodeling, as changes in histone modification and DNA methylation 
have been found in tumor cells.  
Proteins secreted by the tumor modify the microenvironment by contributing growth factors and 
proteases that degrade the extracellular matrix, and affect cell motility and adhesion. Stromal cells 
secrete ECM proteins, cytokines, growth factors, proteases, protease inhibitors, and 
endoglycosidases such as heparanase. These proteins modify the ECM in what is thought to be a 
systematic manner. Osteopontin, galectin-3, transforming growth factor-β and matrix 
metalloproteinases (MMP) are important secreted proteins closely associated with cancer 
development (43). MMP are expressed at higher levels by tumor-associated epithelial cells than by 
normal epithelial cells. These MMP revise the composition of the EMC by degrading the basement 
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membrane and other ECM proteins. This increase in proteolytic activity may also act to support 
tumor malignancy. Extreme shifts in the inhibition of protease activity by plasminogen activation 
inhibitor-1 (PAI-1), either by its absence or by excessive levels, demonstrate an anti-angiogenic 
effect in mouse cells, while physiological levels of PAI-1 support angiogenesism (44). Tissue 
inhibitors of metalloproteinases (TIMP) are endogenous inhibitors of MMP and may function to 
balance the protease activity of MMP to shift the balance from a pro-angiogenic to an inhibitory 
environment. 
Targeting the tumor microenvironment may be a feasible therapeutic approach for cancer treatment 
and prevention. In contrast to genetically unstable tumor cells, the genetically stable cells 
composing the microenvironment are less plastic and less likely to acquire drug resistance, and 
therefore potentially make better targets for cancer therapy (45). In line with this, anti-angiogenic 
drugs have been developed to target tumor endothelial cells as a means of cancer treatment (46). 
 
 
1.6 CANCER AND INFLAMMATION 
 
Central to the development of cancer are genetic changes that endow these “cancer cells” with 
many of the hallmarks of cancer, such as self-sufficient growth and resistance to antigrowth and 
pro-death signals. However, while the genetic changes that occur within cancer cells themselves, 
such as activated oncogenes or dysfunctional tumor suppressors, are responsible for many aspects 
of cancer development, they are not sufficient. Tumor promotion and progression are dependent on 
ancillary processes provided by cells of the tumor environment but that are not necessarily 
cancerous themselves. Inflammation has long been associated with the development of cancer (47) 
(Fig.13). 
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Figure 13: Hallmarks of Cancer. 
 
Epidemiological studies have shown that chronic inflammation predisposes individuals to various 
types of cancer. It is estimated that underlying infections and inflammatory responses are linked to 
15–20% of all deaths from cancer worldwide (48). There are many triggers of chronic inflammation 
that increase the risk of developing cancer. Such triggers include microbial infections (for example, 
infection with Helicobacter pylori is associated with gastric cancer and gastric mucosal lymphoma), 
autoimmune diseases (for example, inflammatory bowel disease is associated with colon cancer) 
and inflammatory conditions of unknown origin. 
The main function of the mammalian immune system is to monitor tissue homeostasis, to protect 
against invading or infectious pathogens and to eliminate damaged cells. Therefore, it is surprising 
that cancer occurs with such a high frequency in humans. Clinical and experimental studies indicate 
that innate and adaptive immune cells are significant, albeit sometime paradoxical, determinants of 
epithelial tumorigenesis. Links between cancer and inflammation were first made in the nineteenth 
century, on the basis of observations that tumors often arose at sites of chronic inflammation and 
that inflammatory cells were present in biopsy samples from tumors.  
Recent data have expanded the concept that inflammation is a critical component of tumour 
progression. It is now becoming clear that the tumour microenvironment, which is largely 
orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, 
fostering proliferation, survival and migration. The hallmarks of cancer-related inflammation 
include the presence of inflammatory cells and inflammatory mediators (for example, chemokines, 
cytokines and prostaglandins) in tumour tissues, tissue remodeling and angiogenesis similar to that 
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seen in chronic inflammatory responses, and tissue repair. These signs of ‘smouldering’ 
inflammation (49) are also present in tumours for which a firm causal relationship to inflammation 
has not been established (for example, breast tumours). Indeed, inflammatory cells and mediators 
are present in the microenvironment of most, if not all, tumours, irrespective of the trigger for 
development. The connection between inflammation and cancer can be viewed as consisting of two 
pathways: an extrinsic pathway, driven by inflammatory conditions that increase cancer risk (such 
as inflammatory bowel disease); and an intrinsic pathway, driven by genetic alterations that cause 
inflammation and neoplasia (such as oncogenes) (Fig.14). 
The intrinsic pathway is activated by genetic events that cause neoplasia. These events include the 
activation of various types of oncogene by mutation, chromosomal rearrangement or amplification, 
and the inactivation of tumour-suppressor genes. Cells that are transformed in this manner produce 
inflammatory mediators, thereby generating an inflammatory microenvironment in tumours for 
which there is no underlying inflammatory condition (for example, breast tumours). By contrast, in 
the extrinsic pathway, inflammatory or infectious conditions augment the risk of developing cancer 
at certain anatomical sites (for example, the colon, prostate and pancreas). The two pathways 
converge, resulting in the activation of transcription factors, mainly nuclear factor-κB (NF-κB), 
signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1α 
(HIF1α), in tumour cells. These transcription factors coordinate the production of inflammatory 
mediators, including cytokines and chemokines, as well as the production of cyclooxygenase 2 
(COX2) (which, in turn, results in the production of prostaglandins). These factors recruit and 
activate various leukocytes, most notably cells of the myelomonocytic lineage. The cytokines 
activate the same key transcription factors in inflammatory cells, stromal cells and tumour cells, 
resulting in more inflammatory mediators being produced and a cancer-related inflammatory 
microenvironment being generated. Smouldering cancer-related inflammation has many tumour-
promoting effects (50). 
INTRODUCTION 
  
 
38 
 
 
Figure 14: Pathway that connect inflammation and cancer. 
 
To understand the role of inflammation in the evolution of cancer, it is important to understand 
what inflammation is and how it contributes to physiological and pathological processes such as 
wound healing and infection (Fig.15). 
Normal tissues have a highly organized and segregated architecture. Epithelial cells sit atop a 
basement membrane separated from the vascularized stromal (dermis) compartment. Upon 
wounding or tissue assault, platelets are activated and form a haemostatic plug where they release 
vasoactive mediators that regulate vascular permeability, influx of serum fibrinogen, and formation 
of the fibrin clot. Chemotactic factors such as transforming growth factor-β and platelet-derived 
growth factor, derived from activated platelets, initiate granulation tissue formation, activation of 
fibroblasts, and induction and activation of proteolytic enzymes necessary for remodelling of the 
extracellular matrix (for example, matrix metalloproteinases and urokinase-type plasminogen 
activator). In combination, granulocytes, monocytes and fibroblasts are recruited, the venous 
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network restored, and re-epithelialization across the wound occurs. Epithelial and stromal cell types 
engage in a reciprocal signalling dialogue to facilitate healing. Once the wound is healed, the 
reciprocal signalling subsides (Fig. 15a). Invasive carcinomas, instead are less organized, in fact 
neoplasia-associated angiogenesis and lymphangiogenesis produces a chaotic vascular organization 
of blood vessels and lymphatics where neoplastic cells interact with other cell types (mesenchymal, 
haematopoietic and lymphoid) and a remodelled extracellular matrix. Although the vascular 
network is not disrupted in the same way during neoplastic progression as it is during wounding, 
many reciprocal interactions occur in parallel. Neoplastic cells produce an array of cytokines and 
chemokines that are mitogenic and/or chemoattractants for granulocytes, mast cells, 
monocytes/macrophages, fibroblasts and endothelial cells. In addition, activated fibroblasts and 
infiltrating inflammatory cells secrete proteolytic enzymes, cytokines and chemokines, which are 
mitogenic for neoplastic cells, as well as endothelial cells involved in neoangiogenesis and 
lymphangiogenesis. These factors potentiate tumour growth, stimulate angiogenesis, induce 
fibroblast migration and maturation, and enable metastatic spread via engagement with either the 
venous or lymphatic networks (Fig 15b) (51). 
 
 
Figure 15: Wound healing versus invasive tumour growth. a, Normal tissues have a highly organized and segregated 
architecture; b, Invasive carcinomas are less organized. 
 
 In response to tissue injury, a multifactorial network of chemical signals initiate and maintain a 
host response designed to ‘heal’ the afflicted tissue. This involves activation and directed migration 
of leukocytes (neutrophils, monocytes and eosinophils) from the venous system to sites of damage 
INTRODUCTION 
  
 
40 
 
and tissue mast cells also have a significant role. For neutrophils, a four-step mechanism is believed 
to coordinate recruitment of these inflammatory cells to sites of tissue injury and to the provisional 
extracellular matrix (ECM) that forms a sCAFfolding upon which fibroblast and endothelial cells 
proliferate and migrate, thus providing a nidus for reconstitution of the normal microenvironment. 
These steps involve: activation of members of the selectin family of adhesion molecules (L- P-, and 
E-selectin) that facilitate rolling along the vascular endothelium; triggering of signals that activate 
and upregulate leukocyte integrins mediated by cytokines and leukocyte-activating molecules; 
immobilization of neutrophils on the surface of the vascular endothelium by means of tight 
adhesion through α4β1 and α4β7 integrins binding to endothelial vascular cell-adhesion molecule-1 
(VCAM-1) and MadCAM-1, respectively; and transmigration through the endothelium to sites of 
injury, presumably facilitated by extracellular proteases, such as matrix metalloproteinases 
(MMPs).  
The profile of cytokine/chemokines persisting at an inflammatory site is important in the 
development of chronic disease. The pro-inflammatory cytokine TNF-α (tumour necrosis factor-α) 
controls inflammatory cell populations as well as mediating many of the other aspects of the 
inflammatory process. TGF-β1 is also important, both positively and negatively influencing the 
processes of inflammation and repair (52). The key concept is that normal inflammation is usually 
self-limiting; however, dysregulation of any of the converging factors can lead to abnormalities and 
ultimately, pathogenesis. Neutrophils (and sometimes eosinophils) are the first recruited effectors of 
the acute inflammatory response. Monocytes, which differentiate into macrophages in tissues, are 
next to migrate to the site of tissue injury, guided by chemotactic factors. Once activated, 
macrophages are the main source of growth factors and cytokines, which profoundly affect 
endothelial, epithelial and mesenchymal cells in the local microenvironment. Mast cells are also 
important in acute inflammation owing to their release of stored and newly synthesized 
inflammatory mediators, such as histamine, cytokines and proteases complexed to highly sulphated 
proteoglycans, as well as lipid mediators.  
Cytokine and chemokine balances regulate neoplastic outcome. The balance of cytokines in any 
given tumour is critical for regulating the type and extent of inflammatory infiltrate that forms. 
Tumours that produce little or no cytokines or an overabundance of anti-inflammatory cytokines 
induce limited inflammatory and vascular responses, resulting in constrained tumour growth. In 
contrast, production of an abundance of pro-inflammatory cytokines can lead to a level of 
inflammation that potentiates angiogenesis, thus favouring neoplastic growth. Alternatively, high 
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levels of monocytes and/or neutrophil infiltration, in response to an altered balance of pro-versus 
anti-inflammatory cytokines, can be associated with cytotoxicity, angiostasis and tumour 
regression. In tumours, interleukin-10 is generally a product of tumour cells and tumour-associated 
macrophages. (Fig.16) (51). 
 
 
Figure 16: Cytokine and chemokine balances regulate neoplastic outcome. 
 
Yet, the recruitment of inflammatory cells may also be counterproductive for tumour development, 
and also may represent an attempt by the host to suppress tumour growth (53). The pro-tumour 
actions of inflammatory cells include releasing growth and survival factors, promoting angiogenesis 
and lymphangiogenesis, stimulating DNA damage, remodelling the ECM to facilitate invasion, 
coating tumour cells to make available receptors for disseminating cells via lymphatics and 
capillaries, and evading host defense mechanisms. Although inflammatory responses should also be 
anti-tumour, cancer patients are often defective in their inflammatory responses. This may arise by 
two distinct tumour-mediated mechanisms: a failure to upregulate the anti-inflammatory cytokines, 
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or subversion of the host response resulting from desensitization of receptors owing to high 
chemokine and cytokine concentrations that then blunt systemic responses. 
The challenge for the future is to normalize the inflammatory network to regain a normal host 
response overall: decreasing the high levels of tumour-promoting properties of the infiltrating cells, 
such as pro-inflammatory cytokines, while increasing their tumour-suppressing properties, such as 
anti-inflammatory cytokines. In this way, later in tumour progression, we can harness the activities 
that are antitumour while suppressing those that are pro-tumour. 
 
 
1.6.1 INTERFERONS 
 
Interferons (IFNs) are a diverse family of pleiotropic cytokines in humans typically divided among 
three IFN classes: Type I IFN, Type II IFN, and Type III IFN. All classes are very important for 
fighting viral infections. Interferons (IFNs) belong to the large class of glycoproteins known as 
cytokines. Interferons are named after their ability to "interfere" with viral replication within host 
cells but they have other functions: activate immune cells, such as natural killer cells and 
macrophages; increase recognition of infection or tumor cells by up-regulating antigen presentation 
to T lymphocytes; and  increase the ability of uninfected host cells to resist new infection by virus. 
They allow for communication between cells to trigger the protective defenses of the immune 
system that eradicate pathogens or tumors. 
IFNs play an essential role in innate immunity by inhibiting the replication and spread of viral, 
bacterial, and parasitic pathogens. They also modulate immune responses and exert antiproliferative 
effects in some cell types. As a result of these functions, IFNs are used in the clinic to treat certain 
viral infections, some cancer types, and multiple sclerosis. IFNs mediate their effects by binding to 
cell surface receptors activating members of the JAK kinase family of proteins. Activated JAK 
kinases phosphorylate the signal transducers and activators of transcription (STAT) family of 
transcription factors. The STAT proteins homo- or heterodimerize and form complexes with other 
transcription factors to activate transcription of IFN-stimulated genes (ISGs) (54). The gene 
products regulated by IFNs are the primary effectors of the IFN response. Although the functions of 
most ISGs remain to be elucidated, some of the best studied ISGs play pivotal roles in host defense. 
Experiments using mice indicate the IFNs are essential for innate immunity against viral infections. 
Mice with a targeted disruption of the type I or II IFN receptor genes are extremely susceptible to 
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viral infections. IFNs induce the production of several known antiviral proteins including the 
double-stranded RNA dependent kinase “protein kinase RNA-regulated” (PRKR), a family of 
29,59-oligoadenylate synthetases that lead to the activation of RNase L and the Mx proteins, all of 
which have been shown to restrict the growth of certain viruses (55). However, the inhibition of 
viral replication induced by IFNs is only partially dependent on these particular ISGs, because mice 
triply deficient for PRKR, RNase L, and Mx1 genes retain partial responsiveness to the antiviral 
effects of IFNs (56). These results imply that other as-yet-unidentified ISGs are also potent antiviral 
effectors. 
 
 
1.7 MICROARRAY TECHNOLOGY  
 
Microarray technology evolved from Southern blotting, where fragmented DNA is attached to a 
substrate and then probed with a known DNA sequence. A microarray (also commonly known as 
DNA chip or biochip) is a collection of DNA spots attached to a solid surface. This technology is 
used to measure the expression levels of large numbers of genes simultaneously or to genotype 
multiple regions of a genome. Each DNA spot contains picomoles (10−12 moles) of a specific DNA 
sequence, known as probes (or reporters or oligos). These can be a short section of a gene or other 
DNA element that are used to hybridize a cDNA or cRNA (also called anti-sense RNA) sample 
(called target) under high-stringency conditions. Probe-target hybridization is usually detected and 
quantified by detection of fluorophore-, silver-, or chemiluminescence-labeled targets to determine 
relative abundance of nucleic acid sequences in the target. 
Since an array can contain tens of thousands of probes, a microarray experiment can accomplish 
many genetic tests in parallel. Therefore arrays have dramatically accelerated many types of 
investigation. In standard microarrays, the probes are synthesized and then attached via surface 
engineering to a solid surface by a covalent bond to a chemical matrix (via epoxy-silane, amino-
silane, lysine, polyacrylamide or others). The solid surface can be glass or a silicon chip, in which 
case they are colloquially known as an Affy chip when an Affymetrix chip is used. Other microarray 
platforms, such as Illumina, use microscopic beads, instead of the large solid support. Alternatively, 
microarrays can be constructed by the direct synthesis of oligonucleotide probes on solid surfaces. 
DNA arrays are different from other types of microarray only in that they either measure DNA or 
use DNA as part of its detection system. Microarrays also differ in fabrication, workings, accuracy, 
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efficiency, and cost. Many types of arrays exist and the broadest distinction is whether they are 
spatially arranged on a surface or on coded beads: 
 The traditional solid-phase array is a collection of orderly microscopic "spots", called 
features, each with a thousands of identical and specific probes attached to a solid surface, 
such as glass, plastic or silicon biochip (commonly known as a genome chip, DNA chip or 
gene array). Thousands of these features can be placed in known locations on a single DNA 
microarray. 
 The alternative bead array is a collection of microscopic polystyrene beads, each with a 
specific probe and a ratio of two or more dyes, which do not interfere with the fluorescent 
dyes used on the target sequence. 
DNA microarrays can be used to detect DNA (as in comparative genomic hybridization), or detect 
RNA (most commonly as cDNA after reverse transcription) that may or may not be translated into 
proteins. The process of measuring gene expression via cDNA is called expression analysis or gene 
expression profiling.  
Depending upon the kind of immobilized sample used to construct the arrays and the information 
fetched, the Microarray experiments can be categorized in three ways: 
1. Microarray Expression Analysis: in this experimental setup, the cDNA derived from the 
mRNA of known genes is hybridized. Gene expression microarray can be single-or double channel. 
In the former case all samples are labeled with the same dye and independently hybridized. Single 
gene expression levels are derived by comparing intensities between the different samples after 
appropriate normalization procedures. In the two channel arrays, each sample is compared to a 
reference (e.g. an RNA sample obtained by an appropriate mixture of tumor samples, cell lines, etc) 
or to a different type of sample (e.g. normal tissue vs tumor tissue). Samples and reference are 
labeled with different dyes, and the obtained colored spots reflects the relative abundance for each 
gene among the two samples. The sample has genes from both the normal as well as the diseased 
tissues. Spots with more intensity are obtained for diseased tissue gene if the gene is over expressed 
in the diseased condition. This expression pattern is then compared to the expression pattern of a 
gene responsible for a disease. 
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2. Microarray for Mutation Analysis: for this analysis, the researchers use gDNA. The genes 
might differ from each other by as less as a single nucleotide base.  
A single base difference between two sequences is known as Single Nucleotide Polymorphism 
(SNP) and detecting them is known as SNP detection. 
3. Comparative Genomic Hybridization: it is used for the identification in the increase or 
decrease of the important chromosomal fragments harboring genes involved in a disease. 
Microarrays can be used for different purposes: 
Gene Discovery: DNA Microarray technology helps in the identification of new genes, gain 
knowledge about their function and expression levels under different conditions. 
Disease Diagnosis: DNA Microarray technology helps researchers learn more about different 
diseases such as heart diseases, mental illness, infectious disease and especially the study of cancer. 
Until recently, different types of cancer have been classified on the basis of the organs in which the 
tumors develop. Now, with the evolution of microarray technology, it will be possible for the 
researchers to further classify the types of cancer on the basis of the patterns of gene activity in the 
tumor cells. This will tremendously help the pharmaceutical community to develop more effective 
drugs as the treatment strategies will be targeted directly to the specific type of cancer. 
Drug Discovery: Microarray technology has extensive application in Pharmacogenomics. 
Pharmacogenomics is the study of correlations between therapeutic responses to drugs and the 
genetic profiles of the patients. Comparative analysis of the genes from a diseased and a normal cell 
will help the identification of the biochemical constitution of the proteins synthesized by the 
diseased genes. Specific genes coding for specific proteins may emerge this way as druggable 
targets. 
Toxicological Research: Microarray technology provides a robust platform for the research of the 
impact of toxins on the cells and their passing on to the progeny. Toxicogenomics establishes 
correlation between responses to toxicants and the changes in the genetic profiles of the cells 
exposed to such toxicants. 
In the recent past, microarray technology has been extensively used and over the years, an 
enormous amount of data related to gene expression has been generated . This data is scattered and 
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is not easily available for public use. To facilitate accessibility to this data, the National Center for 
Biotechnology Information (NCBI) has created the Gene Expression Omnibus or GEO. It is a 
data repository facility which includes data on gene expression from varied sources .Many of the 
gene expression data are also linked to clinical information. 
Nevertheless the heterogeneity of platforms used has raised some skepticism about the reliability, 
reproducibility and comparability of microarray data. A study conducted by the Food and Drug 
Administration as a project called Microarray Quality Control (MAQC) has dispelled many doubts 
thanks to the analysis of data from 137 participants from 51 academic and industrial partners 
obtained from the use of different platforms (Illumina, Agilent and Affymetrix). The reproducibility 
of microarray data was found to be comparable to that of commonly used diagnostic tests, such as 
immunohistochemistry and evaluation of the histological grade (57). 
 
 
1.7.1 GENE EXPRESSION PROFILES OF BREAST CANCER: STATE OF THE 
ART 
 
In cancerous disease many genes are altered. The definition of the gene expression profile of the 
tumor allowed a molecular classification of cancer to better understand the prognostic classification, 
a more accurate prediction of response to treatment and the aggressiveness of the disease (58). 
 Gene expression analysis offers a systematic approach for the prediction and identification of new 
gene functions, and molecular characteristics (59) useful for the development of new drugs and new 
potential therapeutic strategies (60). 
The successes achieved by the administration of trastuzumab and tamoxifen in patients respectively 
ERBB2-positive and ER-has demonstrated the importance to identify a priori the patients who 
would benefit of a particular treatment (59). Finally, of great interest from the point of view 
pharmacogenomics, is the study of gene expression in the course of a specific treatment.  
- Development of multigene expression signatures in breast cancer 
One of the first studies undertaken with microarray in breast cancer has led to the definition of a 
molecular classification of this highly heterogeneous neoplasm (61;62). Based on the gene 
expression profile 5 molecular classes were identified: 
1) luminal A,  
2) luminal B,  
3) basal-like tumors, 
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4) ERBB2 positive tumors and  
5) normal breast-like tumors (63). 
 The recognition of a distinct expression profile between different tumor subtypes has allowed us to 
better understand the biology and has contributed to a new vision of breast cancer, not as a single 
disease, but as a set of several biologically distinct diseases. 
 This observation is changing the design of trials of new drugs because it is now clear that the 
molecular type stratification is a necessary strategy to improve the response to each treatment. 
Clinical pathological variables are not able to describe the heterogeneity of breast cancer, as 
patients with the same clinical stage and pathological grade show a wide spectrum of variability in 
treatment response and prognosis.  
It is therefore necessary to develop classifiers based on multigene expression signature, allowing a 
better patient stratification. The classes considered for stratification of patients for treatment 
purposes are generally good and bad prognosis, but such classes may be any other feature for which 
it is possible to define a training set of data.  
- Prediction of prognosis 
With microarray technique it investigated the heterogeneity of disease in order to develop tools 
(gene signature) to improve outcome prediction compared traditional prognostic factors. 
In literature there are numerous examples, mainly based on two different approaches: 
 • TOP-DOWN approach: comparison of gene expression profiles of tumors from groups of patients 
with known disease outcome, in order to identify differentially expressed genes (class comparison) 
between the groups without any assumption biological a priori. 
 • BOTTOM-UP approach or hypothesis-driven approach: selected gene associated to specific 
phenotypes or pathways are a priori identified based on previous biological knowledge pathway 
and their correlation with disease outcome is tested. The so-called CANDIDATE GENES approach 
is a specific type of bottom up approach where a multivariate predictor is built combining gene 
expression data of a limited series of selected genes on the basis of biological knowledge. 
 -Prediction of treatment response 
The improvement of the prognostic tools will play a fundamental role in the future both for the 
identification of patients at high risk of recurrence disease to be subjected to aggressive treatments 
and to avoid unnecessary treatments and toxicity in low-risk patients. 
However, is also important to identify which is the optimal therapy for each patient. In oncology the 
ultimate goal of functional genomics is the definition of personalized therapy. 
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 The molecular markers that are routinely used in breast cancer study are the estrogen receptor 
(ER), progesterone receptor (PgR) and ERBB2 also known as HER-2/neu. The ER presence 
predicts the tamoxifen and other anti-estrogens response. Due to its low toxicity tamoxifen is used 
in the long term (5 years) in the treatment of ER-positive tumors. Approximately the 70% of tumors 
ER/PgR-positive, the 45% of tumors ER-negative and PgR-positive and only the 34% of tumors 
ER-positive/PgR-negative are responsible to treatment with tamoxifen. ErbB2 is a tyrosine kinase 
receptor overexpressed in 20-30% of cases of breast cancer and is associated with a high risk of 
recurrence and death. The presence of ERBB2 is predictive of the response to trastuzumab 
(Herceptin) (64). 
Therefore the prediction of treatment response based on ER status is not satisfactory. This is mainly 
due to the development of resistance mechanisms that may be of two types: intrinsic (already 
present at the beginning of the treatment) or acquired (induced by the treatment itself). The gene 
profile study has so far been mainly used to understand the intrinsic resistance, and only a few 
studies have faced the problem of acquired resistance through the study of the gene profile after 
treatment in patients treated with neoadjuvant therapy (65). 
 These studies have shown the activation of cytoprotective / antiapoptotic mechanisms in response 
to treatment that may have a general meaning and not just limited to endocrine therapy (66). 
Several randomized studies have also demonstrated the role of neoadjuvant endocrine therapy in 
postmenopausal women with ER+ breast cancer treated with tamoxifen, aromatase inhibitors or 
their combination. These studies offer the possibility to obtain a signature of predictive genes of 
response to treatment (67;68) using the pathological response as a surrogate of the long-term 
benefit.  
With a hypothesis-driven approach (bottom-up approach) going to assess in cell lines modulated 
genes in oncogenic pathways altered in tumors, it was possible to predict the response to treatments 
that had specific targets (69). 
For the hormonal response prediction, in addition to the approach for the development of a priori 
signature, there is the possibility of trying to improve the ER predictability, through the definition 
of a set of genes that better predict the ER status, compared with the immunohistochemistry 
determination or the qPCR that are subject to errors and interlaboratory variability (70).  
At the moment, few studies have identified predictors of response to chemotherapy. The problem is 
particularly complex because the treatment response depends both of prognosis and of individual 
sensitivity and it is therefore important to stratify patients according to the risk. This approach is 
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possible only by development of risk molecular predictors that allow a uniform stratification of 
patients and especially layering on a continuous scale. 
 The data are still very preliminary, but they are encouraging. It is also important emphasize that 
significant contributions can also arise from the gene profile retrospective study of patients involved 
in the first chemotherapy historical trials. The limit to study partially overcome treatments is largely 
offset by the possibility of having available a control arm. Moreover these studies have still 
technical difficulties related to the poor quality of RNA extracted from archival material of decades 
ago, but rapid progress in the design of new technologies for the study of the transcriptome will 
certainly overcome this obstacle. 
 
 
1.7.2 SUB-TYPES BREAST CANCER IDENTIFIED BY GENE EXPRESSION 
PROFILING 
 
Perou and Sorlie group, through the analysis of gene expression profiles have identified five 
molecular subtypes of breast cancer (62;71;72). 
These studies represented a milestone in the biology of breast cancer study. Sorlie et al. have 
characterized the variation in gene expression patterns in a set of 65 surgical specimens of breast 
tumours from 42 different individuals, using complementary DNA microarrays representing 8,102 
human genes. These patterns provided a distinctive molecular portrait of each tumour. Twenty of 
the tumours were sampled twice, before and after a 16-week course of doxorubicin chemotherapy, 
and two tumours were paired with a lymph node metastasis from the same patient.  
 Gene expression patterns in two tumour samples from the same individual were almost always 
more similar to each other than either was to any other sample. By grouping the samples into 
clusters using those genes which were more variable among samples from different patients 
compared to replicate samples from the same patient, it was observed that the majority of tumors 
belonging to the same pair clusterized together on the terminal branches of the dendrogram, 
pointing out that, despite the potential sources of variability due to different sample preparation and 
chemotherapy treatment, each tumor was more similar to its paired tumor, compared to all others. 
This implies that each cancer is unique and has a distinctive pattern of gene expression. The 
researchers then exploited the advantage linked to the availability of the pairs of tumors to explore 
the possibility of identifying signature of genes able to discriminate between the different subtypes 
tumor. A pattern of gene expression, useful for the classification of tumors, it must include genes 
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expressed in similar samples taken from the same tumor, but expressed in a different way compared 
to other cancers. The pairs of tumors of the same patients represented a unique opportunity for the 
systematic search of genes whose expression levels reflected the intrinsic characteristics of these 
tumors. When variation in expression of this set of genes was used to order the tissue samples, 17 of 
the 20 'before and after' doxorubicin pairs were grouped together as were both of the tumour/lymph 
node metastasis pairs. 
Sets of co-expressed genes were identified for which variation in messenger RNA levels could be 
related to specific features of physiological variation. From the genes whose expression was well 
measured in the 65 tissue samples was selected a subset of 496 genes (termed the 'intrinsic' gene 
subset) that consisted of genes with significantly greater variation in expression between different 
tumours than between paired samples from the same tumour. 
The tumours could be classified into subtypes distinguished by pervasive differences in their gene 
expression patterns. The dendrogram appear in two main branches, which are subdivided into 
smaller clusters, for which they can be identified specific biological characteristics. Branches are 
colored and each colors represent one of the four subtypes: basal-like, orange; Erb-B2 +, pink; 
normal-breast-like, light green; and luminal epithelial/ER+, dark blue and the small black bars 
beneath the dendrogram identify the 17 pairs that were matched by this hierarchical clustering; 
larger green bars identify the positions of the three pairs that were not matched by the clustering 
(71) (Fig.17). 
 
Figure 17: Experimental sample associated cluster dendrogram. 
 
In their subsequent studies Perou and Sorlie, have further refined the division into subtypes and 
redefined the list of genes intrinsic (62;72). 
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 They produced a new list of 540 genes intrinsic, many of which are in common with the first one. 
The overall pattern of expression of these genes showed the existence of two major groups of 
tumors that express or not the genes characteristic of luminal cells, including of course ESR1.  
The largest number of analyzed samples also made it possible to divide the group into two 
subgroups of tumors luminal (Fig.18-A). Among these, the larger group, called Luminal-A, is 
represented by tumors with high expression of the gene of the estrogen receptor (ESR1), LIV-1 
protein, regulated by ESR1, and GATA-binding protein 3 (GATA3) (Fig. 18-F). The second group 
of cancers, called Luminal-B, show a medium or low expression of specific luminal tumors genes, 
including the cluster of genes associated with the ER, but is further distinguished from the luminal-
A for the high expression of a new set of genes as GGH, LAPTMB4, NSEP1 and CCNE1, but 
whose function is unknown (Fig.18-C). The subtype to the basal epithelial cells linked is 
characterized by the high expression of KRT5 and KRT17 and is completely negative for the cluster 
of luminal/ER genes (Fig. 18-D), while the ERBB2 subtype is characterized by a high expression of 
many genes contained ERBB2 oncogene, including ERBB2 same, GRB7 and TRAP100 (Fig18-B). 
Finally has been highlighted a group of tumors normal-like, similar to normal tissue, showing high 
expression of many genes known to be expressed by adipose tissue and other types of non-epithelial 
cells (Fig. 18-E). These tumors also showed strong expression of the genes of the basal cells and 
low expression of luminal genes. However it is not yet clear whether these tumors represent a real 
molecular subtype or simply be a reflection of sample contamination by normal cells. 
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Figure 18: Hierarchical Clustering with the subset of the 540 genes intrinsic. A-Dendrogram of samples. The branches 
that correspond to samples with a low correlation to each subtype are colored in gray. B-cluster of genes associated with 
ERBB2. C-cluster associated with the luminal subtype-B. D-cluster associated with the basal epithelial cells. E-cluster 
of genes important for normal-like tumors. F-cluster of genes associated with the luminal subtype-A, containing the 
gene for the ER.  
 
To understand whether the five different tumor subtypes identified by hierarchical clustering could 
represent clinically distinct groups of patients in the same study was performed univariate survival 
analysis, comparing the subtypes with respect to overall survival and disease-free survival. The 
Kaplan-Meier analysis, constructed by excluding the group of normal-like, showed a significant 
difference in overall survival between patients belonging to different subtypes (Fig.19-A). 
Specifically, the basal-like and ERBB2 subtypes are associated with a lower survival. Over-
expression of onco-ERBB2 protein is a prognostic factor recognized, associated with poor survival 
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in breast cancer and this is also verified for subtype ERBB2 defined in the study. The most 
interesting result is the significant difference in survival observed between tumors luminal-A and 
luminal-B. The luminal-B tumors may represent a clinically distinct group with a worse course of 
the disease, particularly with respect to relapse. Perhaps this subtype may reflect a group of patients 
who are less likely to benefit from adjuvant therapy with tamoxifen, despite positivity for the 
estrogen receptor. Further the clinical relevance of the subtypes is highlighted by similar expression 
of some genes between luminal-B and ER-negative tumors, and basal-like subtypes and ERBB2, 
suggesting that high levels of expression of these genes may be associated with poor prognosis. 
After Perou and Sorlie identification of the five molecular subtypes, it was necessary a validation in 
independent datasets.  The robustness of the tumor subtypes has been tested conducting similar 
analyzes on published dataset by van't Veer and colleagues (73). The hierarchical clustering was 
used exactly as described in previous work, to highlight the expression patterns of intrinsic gene in 
97 tumor samples. Of the 540 intrinsic genes previously identified, 461 were evaluable in van't Veer 
dataset also. As expected, the clearer distinction was between tumors with high levels of ER-related 
genes cluster and tumors that were negative for these genes, which exhibited a gene expression 
profile characteristic of cancer basal-like and ERBB2. Even the division into luminal-A and B was 
observed, but was less clear, while the basal-like tumors were reconfirmed as the more 
homogeneous group, with a high correlation degree between them and a well separated cluster from 
other subtypes. To test whether the subtypes were associated with significant differences in 
prognosis, even in this cohort of patients, the investigators performed a Kaplan-Meier univariate 
analysis with respect to time of development of distant metastases. As shown in Fig.19-B, the 
probability of remaining disease-free is significantly different between the subtypes: patients with a 
tumor-luminal A have a longer disease-free interval, while the groups basal-like and ERBB2 show 
an interval time shorter disease-free. 
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Figure 19: Kaplan–Meier analysis of disease outcome in two patient cohorts. (A) Time to development of distant 
metastasis in the 97 sporadic cases. Patients were stratified according to the subtypes as shown in Fig. 2B. (B) Overall 
survival for 72 patients with locally advanced breast cancer in the Norway cohort. The normal-like tumor subgroups 
were omitted from both data sets in this analysis. 
 
The reproducibility of the subtypes was further confirmed in another study, which derived a third 
list of 1300 intrinsic genes. Although this list has been shown to be associated with prognosis in a 
combined dataset of 311 samples from three independent microarray studies. In this study also, it 
was identified a new subtype can be associated with a high expression of genes regulated by 
interferon, but it has not been confirmed in other studies molecular (74). To highlight the 
differences between the different subtypes of breast cancers were used genetic approaches that 
show how different subtypes are associated with specific chromosomal aberrations (75-77). For 
example, on chromosome 16q the loss of genetic material seems to be an event associated with low-
grade tumors and a good prognosis. Roylance and colleagues used the comparative genomic 
hybridization (CGH) for comparing the DNA content of infiltrating ductal carcinomas, grade I, 
predominantly ER-positive, with the DNA content of carcinomas of grade III ER-negative. The 
authors found that 65% of grade I tumors had lost the long arm of chromosome 16, compared to 
16% of grade III tumors, concluding that this chromosomal region contains genes important for 
tumor progression (75). A second study showed that changes in the number of copies of DNA are 
associated with tumor grade, ER status and mutations in the TP53 gene and identified several loci 
associated with poor prognosis. 
p53 is a protein that plays an important role in the control of cellular responses to genotoxic damage 
and regulates the activation of other genes involved in the processes of apoptosis, arrest of cell 
cycle and DNA repair (78). Previous studies have shown that mutations in the TP53 gene, predict a 
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poor prognosis and are associated with a poor response to systemic therapies (79;80).To investigate 
the role of p53 in determining the expression pattern of different subtypes, Sorlie et al performed a 
screening for mutations in the coding region of TP53 in a series of patients. The frequency 
distribution of mutation between the different subtypes was significantly different (p <0.001). The 
group of Luminal-A contained only 16% of mutated tumors, while the luminal-B, ERBB2, and 
basal-like had 71%, 86% and 75% of tumors mutated TP53, respectively (62). The identification of 
TP53 mutations in tumors with high levels of ERBB2 gene, supports the idea of a interdependent 
role between TP53 and ERBB2 (81). To further investigate the TP53 mutations effect on the gene 
expression profile of tumor subtypes, the researchers looked gene differentially expressed between 
TP53 mutated and wild-type tumors. 158 genes correlated with the status of TP53 (FDR <1%) was 
identified (63). As expected, many of the genes highly expressed in cancer basal-like and luminal-B 
genes are regulated by the cell cycle, such as PLK1, CCNA2, STK6, and MAPK13. GRB7 and 
STARD3,two genes co-expressed with the oncogene ERBB2, are included in this list but not the 
gene ERBB2 same. Many genes whose expression is able to distinguish between luminal-A and 
luminal-B, as GGH, and LAPTMB4 MYBL2, are expressed at high levels in mutated tumors. 
Among the genes over-expressed in the wild-type tumors are most of the genes belonging to the ER 
cluster and this summarizes the low rate of mutation present in luminal-A tumors. Further studies 
are needed to determine which of these genes are targets of TP53 and which are only associated 
with a particular phenotype expression. Mutations in the BRCA1 gene predispose to the 
development of early breast cancer. When Sorlie and colleagues added 18 tumors mutated BRCA1 
to the samples used in the clustering analysis, have noticed few differences in expression patterns, 
but all mutated tumors have included in the basal-like cluster (72). This indicates that BRCA1 gene 
mutation predisposes to basal-like tumors development, which is associated with lack of expression 
of estrogen receptor and poor prognosis. As also previously reported, the mutated BRCA1 tumors 
are generally highly proliferative, have mutated TP53 and do not express ER and ERBB2 (82) (83). 
Recent studies have shown that BRCA1 regulates the estrogen and androgen receptor activity, 
providing a link between BRCA1 and hormone-dependent tumors (84). 
Recently Caldas group presents an integrated genomic/transcriptomic analysis of copy number and 
gene expression in breast cancers with long-term clinical outcomes composed of a discovery set of 
997 primary tumours and a validation set of 995 tumours. Inherited variants (copy number variants 
and single nucleotide polymorphisms) and acquired somatic copy number aberrations (CNAs) were 
associated with expression in 40% of genes, with the landscape dominated by cis and trans-acting 
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CNAs. By delineating expression outlier genes driven in cis by CNAs, they identified putative 
cancer genes, including deletions in PPP2R2A, MTAPand MAP2K4. Unsupervised analysis of 
paired DNA–RNA profiles revealed novel subgroups with distinct clinical outcomes, which 
reproduced in the validation cohort. These include a high-risk, estrogen-receptor-positive 11q13/14 
cis-acting subgroup and a favorable prognosis subgroup devoid of CNAs. Their results provide a 10 
novel molecular stratification of the breast cancer population, derived from the impact of somatic 
CNAs on the transcriptome (85). 
 
 
1.7.3 IMMUNOHISTOCHEMISTRY CLASSIFICATION OF LUMINAL AND 
BASAL-LIKE TUMORS 
 
Gene expression profiling has led a major subdivision of mammary tumors respect to expression of 
hormone receptors (luminal tumors), with a gene expression pattern similar to that of the luminal 
cells of the mammary ducts, and tumors that do not express these receptors. This latter category 
include the HER2/neu subtype, the basal-like (with gene expression pattern similar to basal 
epithelial cells of stratified epithelia and my-epithelial cells of the mammary ducts) subtype and the 
normal breast-like subtype, with characteristics similar to normal breast tissue. However, there is a 
complete overlap between the immunohistochemical and gene expression profiling tumors 
classification. 
The basal-like and the normal breast-like are triple negative tumors (ER-, PgR-, HER2/neu-). The 
basal-like subtype is well characterized and they represent about 80% of triple negative tumors and 
10-15% of all breast cancers. The term "basal" is used to indicate a cell population present in 
normal breast tissue expressing high molecular weight cytokeratins (CK) as CK5/6 and CK17, 
which are found at the level of basal cells of various stratified epithelia. The cytokeratins, in 
particular, are the components of cytoskeletal filaments type of that comprise microfilaments, 
intermediate filaments and microtubules, and ensure proper organization and structuring of the 
three-dimensional cytoskeleton inside the epithelial cells (86). Mammary tumors expressing high 
molecular weight cytokeratins were identified by immunohistochemical analysis, already before 
microarray techniques, such as poor prognosis tumors compared to those expressing simple 
cytokeratins. 
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The genes that encode for two markers of cell proliferation, generally used in 
immunohistochemistry, Ki-67 and PCNA, can be also used for the tumor subtypes characterization. 
Basal-like and luminal B subtypes express high levels of these genes associated with proliferation, 
while luminal-A, normal-like and in part also the ERBB2 tumors, are predominantly negative for 
the expression of this gene cluster. This may indicate proliferative differences for each tumor 
subtype, indicating the basal-like subtype as particularly aggressive. The classification at the level 
of this histological subtype, and is then linked to the lack of hormone receptors, EGFR (epidermal 
growth factor c-kit, p63, P cadherin, Ki-6, PCNA, CK5/6, CK14, 17 expression (62). As already 
seen, the luminal tumors, less aggressive compared to basal tumors are characterized by the 
expression of ER, PgR, BCL2, CK8 and CK18 and low expression of CK5, CK5 / 6, CK17, EGFR 
and vimentin (87-89). Cells belonging to the class luminal B, show a low expression of ER and PgR 
and high expression of genes associated with HER2 as ERBB2 and GRB7 that are not found in the 
luminal A tumors, that are low-grade tumors and more favorable prognosis. 
 
 
1.8 RNA EXPRESSION ANALYSIS FROM FORMALIN FIXED-
PARAFFIN EMBEDDED TISSUES 
 
Reports from different clinical studies have shown that DNA microarray technology allows the 
identification of different subtypes within apparently homogeneous diseases (71;90;91) and that the 
identified subtypes often have important clinical implications (62;92). However, the direct 
application this powerful method to the clinical setting has been limited due to its reliance on fresh 
tissue. The majority of studies carried out up to date have used high quality RNA obtained from 
frozen samples and therefore, such studies have been limited by the small number of frozen sample 
collections linked to clinical data. On the other hand, there is instead a huge resource of FFPE 
tissues specimens held in histopathology departments around the world. Formalin-fixed, paraffin-
embedded (FFPE) tissue is the most common specimen available for molecular assays on tissue 
after diagnostic histopathological examination. It represents an invaluable source of information on 
diseases where the patient outcomes are already known. Older archives contain many unique FFPE 
tissue specimens that would be impossible to replicate today due to changes in medical practice and 
technology. These samples provide an invaluable resource for studying the molecular basis of 
disease, making it possible to perform large retrospective studies correlating molecular features 
with therapeutic response and clinical outcome. However extraction of RNA from these tissues has 
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proved to be problematic due to the detrimental effects of formalin-fixation. Over recent years, 
researchers attempting to understand these adverse effects on RNA and identify solutions to remove 
or diminish it have published many reports on the subject. So far gene expression profiling from 
FFPE tissues has been problematic, as the retrieval of RNA from FFPE material is challenging (93). 
Although tissue architecture and proteins are preserved with formalin fixation and paraffin 
embedding, this method does not preserve nucleic acids very well resulting in RNA that is often 
significantly degraded (94). Moreover, formalin fixation causes cross-linkage between nucleic acids 
and proteins (95;96) and covalently modifies RNA by the addition of monomethylol groups to the 
bases, making subsequent RNA extraction, reverse transcription and quantitation problematic 
(97;98). Nearly 40% of adenines as opposed to 4% of uracils acquire monomethylol additions 
following incubation in buffered formalin (99). As a result it has been speculated that the poly A tail 
of fixed mRNA is heavily modified (100) inhibiting oligo (dT) primer annealing to the polyA tail 
and consequently the reverse transcription reaction. In addition, the degraded mRNA may not 
contain a poly A tail for substrate binding by oligo (dT) (101). 
Consequently, significant efforts to improve extraction of RNA from formalin-fixed tissue have 
been made by introducing various modifications to the extraction steps. Masuda et al. showed that 
solubilization of FFPE tissue was not possible by chaotropic agents such as guanidinium 
thiocyanate, which is used in the classic method for RNA extraction from fresh tissue. Instead 
solubilization of FFPE tissue using proteinase K enabled the release of RNA from the cross-linked 
matrix and resulted in almost the same RNA recovery as from a fresh tissue. However following 
extraction such RNAs were still a poor substrates for reverse transcription and subsequent PCR was 
limited to the amplification of small targets. This poor result was attributed to the formalin induced 
monomethylol additions to the nucleic acid bases preventing successful priming of oligo (dT) for 
cDNA synthesis. It was found that approximately half of the monomethylol groups could be 
removed simply by incubating the RNA in formalin-free buffer (Tris, pH 8.5) at 70°C resulting in 
more ‘free’ RNA that could act as template in reverse transcription or PCR. There has been a great 
deal of research into modifying methods for successfully extracting usable RNA from FFPE 
samples (102) and these modifications have been implemented in almost all commercially available 
FFPE extraction methods today. Furthermore, RNA can degrade in the tissue prior to fixation if 
conserved at room temperature and many hospitals do not fix the surgically removed tissue 
immediately. It is therefore important to introduce a change in clinico-pathological routine practice 
for the development of a standardized, consistent and short time interval between removal of 
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specimen and fixation. Additionally, degradation of RNA over time continues whilst the RNA is 
stored in the paraffin block through processes such as oxidation (103;104). New guidelines were 
developed to protect the RNA by impacting on several parameters. Firstly, the pre-fixation time 
(time between surgical incision to fixation), which should be kept as short as possible to reduce 
degradation of RNA (101;105). Secondly, it has been recommended that the fixation time should be 
kept within 12–48 h as longer fixation times can cause further degradation of the samples (106). 
Finally it was suggested that formalin should be buffered to a neutral pH as prolonged tissue 
hypoxia reduces pH in tissues locally, decreasing the yield of nucleic acids. It is clear therefore that 
the adoption of standard operating procedures, at least within the confines of defined clinical trials 
and preferably in all cases, may markedly improve the quality of RNA extracted from FFPE tissue. 
 The major advantage of qRT-PCR is the ability to use very short RNA fragments for amplification, 
which suggests that this method is well suited to the amplification of highly degraded RNA in FFPE 
tissue. RNA fragments extracted from FFPE tissue can be as short as 200 bp and it is therefore 
suggested that amplification of fragments longer than this should not be attempted. Several studies 
have shown that amplicons of less than »130 bp are optimal and show very high success rates 
(106;107). Reverse transcription is the most important part of the qRT-PCR process and success at 
this stage is essential for the generation of cDNA of sufficient yield and quality. Unfortunately, 
monomethylol groups are never removed completely following RNA extraction and purification, 
and these groups, which preferentially bind to adenines, can inhibit substrate annealing of oligo 
(dT) to the poly A tail. It is recommended, that the reverse transcription step is primed either with a 
gene specific primer or random hexamers to ensure detection of a transcript of interest. 
However, despite these optimized procedures RT-PCR from FFPE tissue consistently obtains lower 
Ct values (»5 Cts lower) than for matched fresh frozen tissues with the same input RNA 
(105;107;108). Indicating that a large portion of the RNA is still not accessible for cDNA 
amplification despite improvements to RNA extraction methods from FFPE tissue. 
The preferred source of mRNA for microarray profiling has always been snap frozen tissue material 
(109). And the poor quality associated with RNA from FFPE has often been cited as a primary 
reason for the continued use of fresh frozen tissues, in the clinical application of microarray 
technology (110). However in spite of these difficulties, there have been a few recent reports of 
microarray analysis of RNA extracted from FFPE tissues using T7 in-vitro transcription (IVT) oligo 
(dT) methodologies which have generated valid, reproducible biological data. FFPE extracted 
mRNA is more susceptible to cross hybridization than high quality due to its high degradation. In 
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recent years, there has been a significant drive to develop tools and protocols that enable mRNA 
profiling from more readily available FFPE tissue. It has been demonstrated that the addition of 
random primers to the cDNA synthesis reaction will give higher detection rates from FFPE than 
oligo (dT) priming alone (111). As a result, other commercial amplification kits are becoming 
available specifically for use with degraded RNA or RNA extracted from FFPE tissues. These kits 
utilize not only the oligo (dT) primer in the reverse transcription reaction but also random primers 
to ensure the amplification of RNAs where it has been previously impossible due to the lack of a 
poly A tail or chemical modifications of this sequence. One of these protocols is the recently 
released NuGEN WT-Ovation FFPE system, which has been especially developed by NuGEN 
Technologies Inc for use with RNA extracted from FFPE tissue. This method uses WT-RiboSPIA, 
which is a whole transcriptome amplification system using an isothermal linear nucleic acid 
amplification method. This whole transcriptome amplification strategy was previously used to 
obtain good correlation in gene expression profiles between paraffin-embedded and fresh frozen 
cell pellets (112). Another technology used in measuring gene expression from FFPE samples is the 
DASL (cDNA-mediated annealing, selection, extension and ligation) assay developed by Illumina 
(Illumina Inc., San Diego, CA, USA). The mechanism behind the DASL assay also uses priming 
with random hexamers in the cDNA synthesis stage but with no oligo-d(T) priming. The assay 
works from as little as 50 ng of total RNA to analyze 300–400 transcripts. This is a significant 
increase over what is readily achievable by multiplex RT-PCR, but is still 10–20 fold less than can 
be achieved by using microarray analysis. An initial study by Bibikova et al. found that 90% of the 
genes detected in Fresh frozen samples were detected in FFPE tissue; however, the gene expression 
profiles from FFPE did not correlate exactly with the profiles from fresh samples (R2 = 0.69) (113). 
With the development of high-density microarray platforms that work with FFPE tissue the DASL 
assay may not be an ideal discovery tool. However, while not directly applicable in the biomarker 
discovery process, the DASL assay may have a role in the validation of transcripts previously 
identified by high-density microarray platforms. Almac Diagnostics have adopted a different 
approach to extract robust data from FFPE derived RNA. Almac have developed a range of high 
density Disease Specific MicroArrays (DSAs™) manufactured on the gold standard Affymetrix 
platform, which capture as completely as possible all transcripts transcribed in a specific disease 
setting such as breast, colorectal or non small cell lung cancer. Technically this is extremely 
important as most linear amplification technologies include a reverse transcription step using an 
oligo (dT) primer. This has the effect of enriching for 3’ information, particularly from degraded 
INTRODUCTION 
  
 
61 
 
RNA typically derived from FFPE. It has previously been suggested that a more 3’biased design 
may improve the identification of deregulated genes from FFPE samples (112). The combination of 
extra disease specific content and actual 3’design results in substantially greater detection of robust 
gene expression data from FFPE samples. 
As the reproducibility and reliability of gene expression profiling from FFPE tissue grows, we are 
likely to see a marked increase in the number mRNA based companion diagnostics in routine 
clinical use. 
It is however important to recall that as most clinical studies with gene expression data have been 
performed using the widely-used Affymetrix chips, profiling of FFPE samples with such 
technology has the advantage to allow a direct comparability with previous studies. 
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2. PURPOSE OF THIS THESIS 
 
The clinical problem 
The goal of medicine has been, since its inception, to provide treatment recommendations 
tailored to the illness of an individual. Some of the earliest medical writings clearly document that 
different empirical therapies were recommended for different constellations of symptoms. Thus 
personalized medicine is not per se a new concept. The history of medicine is intricately 
intertwined with technologic developments in diagnostic methods that aim to define disease ever 
more narrowly and to predict with ever increasing precision the clinical outcome with or without 
particular therapies. 
Current medical decision making in oncology takes place in a four-dimensional decision space 
as physicians and patients need to consider the clinical outcome: 
 in the absence of treatment (i.e., prognosis),  
 the probability of benefit from therapy; 
 the risk of adverse events from an intervention.  
An important fourth dimension is patient preference. A person’s willingness to accept therapy is 
influenced by her or his risk tolerance for adverse events from the disease and from the treatment It 
is assumed that the more accurate the prognostic and response predictions and toxicity 
estimates are the more personalized treatment recommendation can be made for an 
individual (Fig.20). 
 
Fig.20: Three-dimensional decision space of predicted prognosis, predicted response to therapy, risk of toxicity, and 
patient preference (114). 
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Several diagnostic tools are commonly used in the context of breast cancer to gage patient 
preference, estimate the risk of recurrence, and estimate the probability of benefit from endocrine or 
trastuzumab therapy (Table 2). Patient preferences are elicited through the medical interview. The 
risk of adverse events is estimated, rather subjectively, on age, co-morbidities, and results from 
simple organ function tests. The risk of recurrence is primarily determined from lymph node status, 
tumor size, and histological grade. Estrogen receptor (ER) and progesterone receptor (PR) 
immunohistochemical results are used to define the subset of individuals who may benefit from 
endocrine therapy, and HER-2 fluorescent in situ hybridization or immunohistochemical analysis 
results are used to select patients for trastuzumab treatment. Several of these clinical and pathologic 
features can be combined into the practically useful and validated multivariable outcome prediction 
model Adjuvant Online (www.adjuvantonline.com). This freely available web-based tool estimates 
the risk of recurrence (or death) with loco regional therapy alone and with various systemic 
adjuvant treatments, including endocrine therapy and chemotherapy for stage I–III breast cancer. 
 
Historical tools to aid medical decision making in breast cancer: 
Variable Method to elicit outcome estimates 
Patient preferences Medical interview 
Risk of adverse events 
Medical history  
Simple organ function tests (BUN, creatinine, liver enzymes, and complete blood 
count) 
Electrocardiogram 
Echocardiogram 
Prognosis 
TNM stage 
Histologic grade 
Adjuvant online software 
Probability of benefit 
 from therapy 
ER and PR immunohistochemical analysis (for endocrine therapy) 
HER-2 fluorescent in situ hybridization or immunohistochemical analysis (for 
trastuzumab therapy) 
 
Table 2: diagnostic breast cancer tools 
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However, current prediction models are suboptimal, individual predictive variables have limited 
accuracy, and the actual clinical outcomes remain heterogeneous in any given prognostic 
group. ER status and HER-2 status are helpful in identifying patients who are not eligible for 
endocrine or trastuzumab therapies by virtue of their high negative predictive values (NPVs) and 
high sensitivities. However, only a minority of ER-positive or HER-2-positive patients respond to 
receptor-targeted therapy. The positive predictive values (PPVs) of these tests are <50%.  
Currently, there are no accepted molecular predictors of response to various 
chemotherapeutic drugs. We also have limited ability to predict adverse events despite the 
relatively high toxicity and modest activity of cytotoxic drugs. These limitations have driven 
biomarker research to develop more accurate molecular predictors of clinical outcome. 
 
The clinical purpose of our study was therefore to obtain a better stratification of patients based on 
risk and treatment benefit to avoid unnecessary toxicity to low risk patients and to plan for 
alternative treatments for high risk patients. 
The above stated purpose was pursued by building gene expression-based predictors. Besides the 
problem of distinguishing pure prognostic from treatment response signatures, we were faced with 
two completely different situations regarding the type of sample used for building the predictors: 
fresh frozen samples on one side and formalin-or Bouin-fixed and paraffin embedded samples on 
the other side (BFPE/FFPE). The type of sample dramatically affects the technical approach and led 
us to work in parallel in two completely different technical contexts. 
 
The technical challenge 
The technical challenge is completely different depending upon the type of sample. In the case of 
frozen sample it is important to obtain high quality RNA samples and to maintain as much as 
possible an uniformity within the technical quality of samples. Degraded samples are therefore 
usually discarded to avoid biases. 
On the contrary fixed sample do not allow to obtain good quality RNA and in such situation 
specific technical protocols to deal with such problem must be developed. 
As we were mainly trying to define a context specific signature, we had to use samples derived 
from clinical trials in a prospective-retrospective design. The majority of samples collected in 
clinical trials are formalin-fixed and paraffin embedded (FFPE) and represents therefore a challenge 
for obtaining good quality gene expression data. The technical purpose of this thesis was therefore 
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to develop a robust pipeline for ‘unlocking’ the biological information contained in FFPE samples. 
This was addressed through: 
Development of specific technical protocols. 
Careful sample pre.-analytical assessment. 
Development of an ad hoc data analysis protocol. 
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3. MATERIALS AND METHODS 
 
3.1 CLINICAL CASES  
 
The FROZEN clinical case study consisted of 127 women with operable breast cancer who are 
underwent conservative or radical surgical resection of the primary tumor at the National Cancer 
Institute of Milan (INTM) from 1983 to 1998. For each patient axillary lymph nodes were analyzed, 
and only women with a negative nodal status were included in the study. 123 samples were 
available for follow-up information. 59 samples were obtained from primary tumors of patients who 
developed metastases within 5 years after surgery and 64 samples from patients that have no 
metastases for a period of more than 5 years. The two groups were selected in order to have similar 
distribution with respect to classical prognostic factors such as ER status, PgR, tumor size and age. 
 
 
3.2 CASISTICA ECTO1 
 
Publicly available Datasets  
We used a set of publicly available datasets downloaded from the Gene Expression Omnibus 
website (http://www.ncbi.nlm.nih.gov/geo/). All datasets contained data from the Affymetrix 
platform. The GSE identification number and the main features of all datasets are listed in the table 
below (Table 3). 
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GSE_ID NAME PLATFORM TISSUE TOT SAMPLES 
SUITABLE 
SAMPLES 
GSE2109 expO Affymetrix PLUS2 breast cancer 353 301 
GSE3744 Richardson Affymetrix PLUS2 breast cancer 47 40 
GSE5460 Lu Affymetrix PLUS2 breast cancer 127 127 
GSE10780 Chen Affymetrix PLUS2 breast cancer 185 42 
GSE12276 Massague Affymetrix PLUS2 breast cancer 204 204 
GSE12763 Hoeflich Affymetrix PLUS2 breast cancer 30 30 
GSE13787 Marty Affymetrix PLUS2 breast cancer 23 23 
GSE16391 Desmedt Affymetrix PLUS2 breast cancer 55 55 
GSE18864 Silver Affymetrix PLUS2 breast cancer 84 75 
GSE19615 Li Affymetrix PLUS2 breast cancer 115 115 
GSE20711 Dedeurwaerder Affymetrix PLUS2 breast cancer 90 88 
GSE21653 Sabatier Affymetrix PLUS2 breast cancer 266 266 
GSE2034 Wang Affymetrix U133A breast cancer 286 286 
GSE2990 Sotiriou Affymetrix U133A breast cancer 189 84 
GSE5327 Minn Affymetrix U133A breast cancer 58 58 
GSE7390 Transbig Affymetrix U133A breast cancer 198 198 
GSE11121 Mainz Affymetrix U133A breast cancer 200 200 
GSE9195 Loi Affymetrix PLUS2 breast cancer 77 77 
GSE6532 Loi2 Both breast cancer 277 277 
GSE12093 Zhang Affymetrix U133A breast cancer 136 136 
GSE17705 Symmans Affymetrix U133A breast cancer 298 195 
GSE26971 Muller Affymetrix U133A breast cancer 277 277 
GSE19246 William Affymetrix PLUS2 DLBCL 2x59 2x56 
 
Table 3: List of Affymetrix dataset 
 
3.3 RNA EXTRACTION FROM FROZEN TISSUE 
 
Fifty to 100 mg of tissue sample were cut from the surgical frozen specimen stored at -80°C, 
homogenized in Teflon previously cooled in liquid nitrogen. Tissue was pulverized using a 
Mikrodismembrator (Braun Biotech International, Germany) and then 1 mL Trizol was added.  
 
 Phase separation  
The homogenized samples were incubated for 5 minutes at room temperature (RT) to permit the 
complete dissociation of nucleoprotein complexes and then centrifuged 10 min at 4°C at 12,000 g 
and the surnatant was transferred in a fresh tube. 0.2 mL of chloroform per 1 mL of TRIZOL® 
Reagent were added. Tubes were shaked vigorously by hand for 15 seconds and incubated at RT for 
2 to 3 minutes. The samples were centrifuged at no more than 12,000 × g for 15 minutes at 4°C. 
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Following centrifugation, the mixture was separated into a lower red, phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remained exclusively in the aqueous phase. 
The volume of the aqueous phase was about 60% of the volume of TRIZOL® Reagent used for 
homogenization (̴600 µL). 
 
 RNA precipitation 
The aqueous phase was transfered to a fresh tube. The RNA was precipitated from the aqueous 
phase by mixing with isopropyl alcohol. 0.5 mL of isopropyl alcohol, per 1 mL of TRIZOL® 
Reagent used for the initial homogenization, was added. Samples were incubated at RT for 10 
minutes and centrifuged at no more than 12,000 × g for 10 minutes at 4°C. The RNA precipitate 
forms a gel-like pellet on the side and bottom of the tube.  
 
 RNA wash 
Supernatant was removed and the RNA pellet was washed with 1,5 mL of 75% ethanol. The sample 
was mixed by vortexing and centrifuged at no more than 7,500 × g for 5 minutes at 4°C.  
 
 Redissolving the RNA  
At the end of the procedure, the RNA pellet was dried (air-dry or vacuum-dry for 5-10 minutes). 
RNA was dissolved in RNase-free water by passing the solution a few times through a pipette. 
RNA was stored at -80°C. 
 
 
3.4 RNA DNase TREATMENT AND CLEAN UP  
 
To eliminate any DNA contamination in RNA samples the RNeasy kit by Qiagen was used. With 
RNase-free water the samples were brought to final volume of 87.5 μl. To each sample we added 10 
μl Buffer RDD and 2.5 μl DNase I stock solution and incubated a RT for 10 min. Thereafter we 
proceeded according to the kit protocol with series of washes to clean up the RNA: 
1. 350 μl Buffer RLT were added and mixed well.  
2. 250 μl ethanol (96–100%) were added to the diluted RNA and mixed well by pipetting 
3. The sample (700 μl) was transfered to an RNeasy Mini spin column placed in a 2 mL collection 
tube and centrifuged for 15 s at 8000 x g. The flow-through was discarded. 
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4. To wash the spin column membrane, two consecutive washes with 500 μl of buffer RPE were 
made and centrifuged for 15 s at  8000 x g the first time,  and 2 min at 8000 x g for the second one. 
The flow-through was discard. 
30 μl RNase-free water was added directly to the spin column membrane to elute the RNA.  
and centrifuged for 1 min at 8000 x g. 
 
 
3.5 NUCLEIC ACID QUANTIFICATION 
 
To quantify the RNA extract and cDNA single strand product with WT-Ovation TM FFPE RNA 
Amplification System V2 (NuGEN) we used Nanodrop ND-2000C (Thermo Scientific). To 
evaluate the concentration of sRNA we used the reading mode ‘ssDNA’. 1µL of the sample was 
placed directly onto the lower measurement pedestal of the NanoDrop. The upper optical pedestal 
was lowered and the measurement was taken. After each reading, the sample was wiped away from 
both the upper and lower pedestals using a clean paper. Each RNA sample was quantified in this 
way. 
In its simplest form the absorbance is measured at 260 and 280 nm. The concentration was 
expressed as ng/ µL. RNA has its absorption maximum at 260 nm and the ratio of the absorbance at 
260 and 280 nm is used to assess the RNA purity of a RNA preparation. Pure RNA has an 
A260/A280 of 2.1. the ratio between absorbance at 260 and 230 nm is used to evaluate a Phenol 
contaminations. The ratio should be 1.7-1.9. It is important that the value was higher than 1.2. 
 
 
3.6 RNA AND cDNA QUALITY  
 
The integrity of RNA samples is essential in the context of gene expression analysis via microarray 
technology or real-time PCR. Total RNA electrophoretic profile was analyzed by the Agilent RNA 
6000 NanoLabChip kit on the Agilent 2100 Bioanalyzer. This analysis quantifies the 28S and 18S 
rRNA species using capillary electrophoresis and applies the RIN (RNA integrity number) 
algorithm to assess RNA quality. RIN ranges from 1 (poor) to 10 (best) (Fig.21). We decided to use 
samples with RIN higher than 6.5.  
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Figure 21: RNA electropherograms: upper figure is a RNA of good quality with high RIN value; bottom figure 
correspond to degraded RNA with low RIN value. 
 
RNA chip was also used to evaluate cDNA single strand product with WT-Ovation TM FFPE RNA 
Amplification System V2 (NuGEN).  For this analysis we did not consider the RIN value, but the 
length of produced amplifications, shown in the electropherogram. If the size of aDNA is higher 
than 200 nt the amplification product can be used for the hybridization on Affymetrix chip 
(Fig.22a), if lower the aDNA was considered inadequate for further microarray analysis (Fig.22b). 
 
 
Figure 22: a. elettropherogram of good quality aDNA; b. elettropherogram of degraded aDNA. 
 
The chip was run according to manufacture instructions. In summary 
 
All reagents were taken out of the fridge to warm at room temperature for at least 30 minutes.  
 Preparation of Gel matrix  
550 µL of gel matrix was added to a spin filter and centrifuged for 10 min at 4000 rpm and 65 µL 
filtered gel was aliquoted into 0.5mL RNase free microfuge tubes.  
a b 
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 Preparation of Gel-dye matrix  
Dye was vortex for 10 seconds and spun down; 1 µL of dye was added to a 65 µL tube of gel matrix 
and vortexed thoroughly for 10 seconds and then centrifuged at maximum speed (13000g or 
14000rpm) for 10 minutes. 
 
 Loading chip with the gel matrix and RNA 6000 Nano Marker:  
A new chip was placed on priming station and 9 µL of gel-dye matrix were loaded into the well 
marked G. The chip priming station was closed and after 30 second the plunger with clip release 
mechanism was release. 9µL of the gel dye matrix were pipetted in the two additional wells marked 
G and later 5 µL of marker were pipette into the well marked ladder and each of the 12 RNA wells. 
 Loading the RNA sample and the RNA 6000 ladder: 
RNA sample and RNA ladder were incubated the in the 70° C heating block for 2 minutes and put 
on ice for 5 minutes. For the aDNA this step was not necessary because the samples were a single 
strand. 
1 µL of ladder was load into the well marked “ladder” and 1 µL of RNA was load into in the chip  
sample wells. 
The chip was place in the adapted vortexer and mixed for 1 minute at 2400rpm. The loaded Chip 
was Place in the Bioanalyzer for the run. 
 
 
3.7 LYMPHOCYTE INFILTRATION SCORE (LI) 
 
Tissue sections stained with haematoxylin and eosin were histologically evaluated by an expert 
pathologist with respect to the extent of inflammatory infiltrate with a 0 to 3 score (none, mild, 
moderate or marked).  
 
 
3.8 IMMUNOHISTOCHEMICAL DETERMINATIONS AND 
EVALUATION OF IHC 
 
IHC was used to evaluate the expression levels of ISG (MX-1, ISG15, OAS2 and IFIT3) and to 
study the different sub/population cells infiltrating tumors.  
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Formalin-fixed, paraffin-embedded whole tumor sections (4µm thick) were dehydrated in xylene, 
rehydratated and processed for autoclave antigen retrieval at 95 ºC in 10 mM Na-citrate buffer for 6 
min. The table reports the characteristics of antibody used. Negative controls were run on each slide 
by omitting the primary antibody. The Ultravision detection system HPR Polymer (Thermo 
Scientific, Astmoor, UK) was used for development. Slides were counterstained with haemotoxylin 
and examined under a light microscope by two independent investigators. 
 
Antibody Clone Dilution  Incubation time Company 
CD4 1F6 1:40 1h TA Novocastra Laboratories, Newcastle upon. 
Tyne, U.K. 
CD8 C8/144b 1:20 1h TA (Dako Corp, Carpinteria, CA 
CD68 KP1 1:1000 1h TA (Dako Corp, Carpinteria, CA 
CD56 123C3.D5 1:400 1h TA Thermo-Scientifics Waltham,USA 
CD57 VC1C 1:50 1h TA Sigma Life Science, St Louis, Mo 
CD3 SP7 1:400 1h TA Thermo-Scientifics, Waltham,USA 
FOXP3 259D/C7 1:200 1h TA BD Pharmingen, NJ, USA 
CD45 PD7/26 1:200 1h TA (Dako Corp, Carpinteria, CA  
CD20 L26 1:400 1h TA (Dako Corp, Carpinteria, CA 
GRANZYME 11F1 1:80 1h TA Novocastra Laboratories, Newcastle upon. 
Tyne, U.K. 
HLADR LN3 1:800 1h TA Thermo-Scientifics, Waltham,USA 
MX1 MPA030917 1:200 1h TA Sigma Life Science, St Louis, Mo 
ISG15 RBO2791 1:100 1h TA Abgent, San Diego, CA 
IFIT3 E-22 1:75 1h TA Santa Cruz Biotechnology, Santa Cruz, CA  
OAS92 H2556/3 1:75 1h TA R&D SYSTEM, Minneapolis, MN USA 
 
Table 4: Antibodies used for immunohistochemical determinations 
 
 
3.9 REVERSE TRANSCRIPTION 
 
To synthesize single-stranded cDNA from total RNA obtained from frozen tissue samples, the 
High-Capacity cDNA Reverse Transcriptions kit (Applied Biosystems) was used. A standard RT 
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protocol was used; 900 ng of RNA in 7,5 µL RNase –free water were reverse transcribed with oligo 
(dT) primer in 15 µL of total reaction volume containing: 
 
 
 
Component Volume/reaction (μL) 
10X RT Buffer 1.5 
25X dNTP Mix (100nM) 0.6 
10X RT Random Primers 1.5 
Multiscribe™ Reverse Transcriptase  0.75 
Nuclease-free H2O 3.15 
Total per reaction 7.5 
 
Table 5: reaction mix 
 
Reverse transcription was performed using the following thermal cycler program: 
 
 
 STEP1 STEP2 STEP3 STEP4 
Temperature (°C) 25 42 85 4 
Time (min) 10 60 5 ∞ 
 
Table 6: thermal cycler RT profile 
 
3.10 REAL TIME PCR 
 
 In order to investigate the ability of the conditioned medium obtained from each type of co-
culture to trigger the interferon response in monoculture of  cancer epithelial cells, we assess 
the expression of some interferon-stimulated genes (ISG), using relative Taqman Gene 
Expression Assays (Applied Biosystems): OAS 2 (2’-5’oligoadenylate synthetase 2), IFIT 3 
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(Interferone induced protein with tetratricopeptide repeats 1), MX1 (gene encoding the 
mixovirus resistance proteins 1) and also STAT 1, an activator of transcription; ACTB and 
GAPDH were used as housekeepimg genes (Table 7). All data were referred to co-culture 
control sample: epithelial cells/epithelial cells. To evaluate the expression of each gene 10 
ng of cDNA for sample was used and the analysis was performed in triplicate.  
The data were analyzed by SDS 2.4 (Applied Biosystems) using a threshold of 0.2 and 
referred as relative quantity respect to a calibrator sample using the 2 –ΔΔCt method. 
 
GENE TaqMan Gene expression Assay (20X) 
OAS 2 Hs00942650_m1 
IFIT 3 Hs00155468_m1 
MX 1 Hs00182073_m1 
STAT 1 Hs01014002_m1 
ACTB Hs03023943_g1 
GAPDH Hs00266705_g1 
 
Table 7: TaqMan Gene expression Assays 
 
 In the pre-analytical sample pre-assessment of the pilot study the expression of the 
housekeeping gene RPL13a was assessed to evaluate the quality of the obtained aDNA, 
using the relative Taqman assay, which allows the amplification of a short sequence of 105 
pb (Hs01926559_g1). 3,3 ng of aDNA were used for each sample and the analysis was 
performed in triplicate; the experiments were run using ‘Absolute Quantification’ set-up. 
The data were analyzed by SDS 2.4 using a threshold of 0.2.  
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PCR reaction mix component Volume (μL) 
TaqMan Fast Universal PCR master 
mix (2X), No Amperase UNG 
7.50 
TaqMan® Gene expression Assay 
(20X) 
0.75 
Template cDNA 1.00 
H2O RNAsi free 5.75 
Total volume for reaction 15 
 
Table 8: Mix of PCR reaction 
 
  Number of cycles: 40 
Temperature (°C) 95 95 60 
Time (min) 0:20 0:01 0:20 
 
Table 9: Thermal cycler PCR profile 
 
Real-time PCR was performed using 96-well plates on 7900HT Real-Time PCR System (Applied 
Biosystems).  
 
 
3.11 RNA ISOLATION FROM FFPE TISSUES  
 
RNA from FFPE material was extracted using the miRNeasy FFPE kit (Qiagen). A 4 µm pre-cut 
section was stained with haematoxylin and eosin and reviewed by a pathologist. Only blocks with > 
70%tumor cells were used.  
From FFPE blocks, 2 sections of 20 µm were cut. For extraction we used manufacture’s instruction: 
 
 Deparaffination: 1mL of xylene was added to the section, vortexed for 10 sec and 
centrifuged at 10,000 rpm for 2 min. 1mL of Ethanol 100% was added to the pellet, 
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vortexed for 10 sec and centrifuged at 10,000 rpm for 2 min. 150 µL of PKD buffer was 
added to the pellet. 
 Proteinase K digestion: 10 µL of proteinase K were added and incubated at 56°C for 2 h and 
then 80°Cfor 15 min, then the samples was keep on ice for 3 min. and centrifuged for 20 
min at 13,500 rpm. 
 DNAse treatment: 16 µL of DNase Booster Buffer and 10 µL of DNase I were added to the 
pellet and incubate a RT for 15 min. 
 RNA isolation: added 320 µL of RBC buffer to adjust binding conditions and than 1120 µL 
of Ethanol 100%. 
 Eluition: total volume was transferred on RNeasy Min Elute column and centrifuged 15 s at 
10,000 rpm. Two washes were done: first with 500 µL of RPE and centrifuged 15 s at 
10,000 rpm, second with 500 µL of RPE and centrifuged 2min at 10,000 rpm. 
RNA was eluted with 15 µL of RNase-free water with centrifugation of 5 min at 14,000 
rpm. 
 
 
3.12 RNA AMPLIFICATION  
 
The NuGEN Ovation FFPE WTA System is a whole transcriptome amplification method that 
enables gene expression studies using precious archive samples of small and degraded RNA in 
FFPE samples 
With the NuGEN protocol, RNAs are reverse transcribed to cDNAs, and amplified during the so-
called SPIA amplification, a linear isothermal DNA amplification process and the finally amplified 
products, consisting of single-strand DNA (ssDNA), are biotin labeled and fragmented according to 
the manufacturer’s guidelines. 
 
Description of Ribo-SPIA® Technology 
Ribo-SPIA technology is a three-step process that generates amplified cDNA from as little as 50 
nanograms of FFPE derived total RNA (Fig.23). 
 
1. Generation of First Strand cDNA 
First strand cDNA was prepared from total RNA using a unique first strand DNA/RNA chimeric 
primer mix and reverse transcriptase (RT). The primers have a DNA portion that hybridizes either 
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to the 5´ portion of the poly(A) sequence or randomly across the transcript. RT extends the 3´ DNA 
end of each primer generating first strand cDNA. The resulting cDNA/mRNA hybrid molecule 
contains a unique RNA sequence at the 5´ end of the cDNA strand. 
 
2. Generation of a DNA/RNA Heteroduplex Double-stranded cDNA  
Fragmentation of the mRNA within the cDNA/mRNA complex creates priming sites for DNA 
polymerase to synthesize a second strand, which includes DNA complementary to the 5´ unique 
sequence from the first strand chimeric primers. The result is a double-stranded cDNA with a 
unique DNA/RNA heteroduplex at one end. 
 
3. SPIA® Amplification 
SPIA is a robust isothermal strand displacement amplification process developed by NuGEN. It 
uses a DNA/RNA chimeric SPIA primer, DNA polymerase and RNase H in a homogeneous 
isothermal assay that provides highly efficient amplification of DNA sequences. RNase H is used to 
degrade RNA in the DNA/RNA heteroduplex at the 5´ end of the first cDNA strand. This results in 
the exposure of a DNA sequence that is available for binding the first SPIA primer. DNA 
polymerase then initiates replication at the 3´ end of the primer, displacing the existing forward 
strand. The RNA portion at the 5´ end of the newly synthesized strand is again removed by RNase 
H, exposing part of the unique priming site for initiation of the next round of cDNA synthesis. The 
process of SPIA DNA/RNA primer binding, DNA replication, strand displacement and RNA 
cleavage is repeated, resulting in rapid accumulation of SPIA cDNA. 
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Figure 23: Ribo-SPIA technology 
 
We amplified 100 ng of total RNA in 5 µL of RNA-free water. To the synthesized first strand 
cDNA 2 µL of the First Strand Enzyme Primer mix were added and incubated for primer annealing 
in pre-warmed thermal cycler at 65°C for 2 min and then the samples were cooled to 4 °C. 
The reaction mix containing (for each sample) 2,5 µL of the First Strand Buffer Mix and 0,5 µL of 
First Strand Enzyme Mix was added to the samples. The reaction was performed using the 
following thermal cycler program: 4°C – 2 min, 25°C – 30 min, 42°C – 15 min, 70°C – 15 min, 
hold at 4°C. 
To the synthesized second strand cDNA a mix containing 9,75 µL of Second Strand Buffer Mix and 
0.25 µL of Second Strand Enzyme mix was added. The reaction was performed with the following 
thermal cycler program: 4°C – 1 min, 25°C – 10 min, 50°C – 30 min, 80°C – 20 min, hold at 4°C. 
 
Next step was the purification of cDNA that consist of three steps after the addition of 32 µL of 
magnetic beads and 10 min of incubation. 
 
1. Binding of cDNA to magnetic bead with 5 min of incubation on the magnet. 
2. Separation of cDNA bound to magnetic beads from contaminants, removing and discarding 
the supernatant. 
3. Three washings, each with 200 µL of ethanol 70%. 
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After air dried the beads on the magnet for a minimum of 20 min, the kit proceeds with Spia 
Amplification using: 
 a master mix 1 with 50 µL of Buffer Mix +20 µL of Spia Primer Mix 1+ 0.7 µL Spia 
Enhancer +10 µL Spia Enzyme Mix. Reaction was ran in thermo-cycler: 4°C – 1 min, 47°C 
– 30 min and cool to 4°C . 
 a master mix 2 with 30 µL of Buffer Mix +20 µL of Spia Primer Mix 2+ 2.3 µL Spia 
Enhancer +30 µL Spia Enzyme Mix. Reaction was ran in thermo-cycler: 4°C – 1 min, 47°C 
– 60 min, heat at 95°C and cool to 4°C. 
 
The beads were separated and discarded from amplified cDNA using the magnet. 
 
3.13 PURIFIATION OF AMPLIFIED CDNA  
 
To purify the cDNA obtained with NuGEN amplification we used the QIAquick PCR purification 
Kit (Qiagen), with some modifications introduced by the NuGEN protocol. 
To 160 µL of amplified cDNA, 800 µL of PB buffer were added. The total volume was loaded onto 
the column and centrifuged for 1 min at 13,000 rpm. Thereafter the columns were washed 2 times, 
each with 700 µL of ethanol 80% and centrifuged 1 min at 13,000 rpm. 
Elution of purified cDNA was done with 30 µL of nuclease-free water with centrifugation 1 min at 
13,000 rpm. 
 
 
3.14 cDNA FRAGMENTATION AND BIOTIN LABELING 
 
Target preparation for Affymetrix GeneChip arrays was performed using 5 µg in 25µL of amplified 
cDNA as input to the NuGEN Encore™ Biotin Module kit. 
The first step was the cDNA fragmentation: a mix containing 5 µL of Buffer Mix +2 µL of 
Fragmentation Enzyme Mix was added to the samples. 
The second step was the labeling, which was performed by adding a mix containing 15 µL of 
Labeling Buffer Mix +1,5 µL of labeling reagent + 1,5 µL of Labeling Enzyme Mix and incubation 
in thermal cycler at 37 °C for 60 min, 70 °C for 10 min and cooling at 4°C. 
 
MATERIALS AND METHODS 
  
 
80 
 
 
3.15  HYBRIDATION CHIP  
 
Frozen samples 
 RNA frozen samples was processed for microarray hybridisation using the Illumina chips. 
800 ng of total RNA were reverse transcribed, labeled with biotin and amplified overnight 
using the Illumina RNA TotalPrep Amplification kit (Ambion, Austin, TX) according to 
manufacturer’s protocol. One μg of the biotinylated cRNA sample was mixed with the Hyb 
E1 hybridization buffer containing 37.5% (w/w) formamide and then hybridized at 58 °C 
overnight to the HumanRef-6_v3 (Illumina, Inc, San Diego, CA) in the case of the 
Discovery Dataset and on the Human-HT 12 v3 in the case of the Metagene Discovery 
dataset. Array chips were washed with manufacturer’s E1BC solution, stained with 1 ug/mL 
Cy3-streptavidine (Amersham Biosciences, Buckinghamshire, UK) and eventually scanned 
with Illumina BeadArray Reader. 
 After purification of the amplified single stranded cDNA obtained from NuGEN Ovation 
FFPE WTA System, 5 µL of  UNG Buffer [10 mM Phosphate buffer (K2HPO4·3H20, 
Sigma-ALDRICH, Inc) and 4 mM MgCl2 (USB)] and 5 µL of  UNG enzyme (Epicentre 
Biotechnologies) were added to 25 µL of total volume containing 5 µg of cDNA. The 
solution was incubated at 50°C for 30 min in a thermal cycler. Following the incubation 5 
µL of labeling buffer [0.952 M Acetic Acid (Sigma-ALDRICH, Inc) and 28 mM MgCl2 
(USB)] 5 µL of ARP solution [11.2 mg/mL ARP (N-aminooxyacetyl)-N’-(D-biotinoyl) 
hydrazine, trifluoroacetic acid salt (Molecular Probes) in 22.4  mM Phosphate buffer] were 
added a the samples and incubated at 50°C for 60 min in a thermal cycler. After purification, 
750 ng biotin-labeled sample were used per Illumina Chip array. The hybridization cocktail 
was prepared according to the Bead Chip manufacturer’s instructions with the exception for 
the hybridation temperature that was reduced to 48°C to accommodate the altered 
hybridization kinetics of cDNA /DNA pairs relative to cRNA/ DNA pairs. 
 
Fixed samples 
FFPE and BFPE samples were profiled comparing different technical approaches in order to define 
the optimal approach to be applied to the clinical samples. 
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 DASL 
Gene expression profiles of RNA derived from FFPE samples were obtained using Illumina DASL 
Cancer Panel (502 genes) or HumanRef-8 WG-DASL v3.0 (24000 genes) (Illumina, San Diego, 
CA, USA) developed specifically to analyze partially degraded RNA. In brief, 200 ng total RNA 
were converted to cDNA using biotinylated oligo-dT18 and random nonamer primers, followed by 
immobilization to a streptavidin-coated solid support. The biotinylated cDNAs were then 
simultaneously annealed to a set of assay-specific oligonucleotides. Extension and ligation of the 
annealed oligonucleotides generated PCR templates that were amplified using fluorescence-labeled 
and biotinylated universal primers. The labeled PCR products were then captured on streptavidin 
paramagnetic beads, washed, and denatured to yield single-stranded fluorescent molecules which 
were hybridized to the Sentrix Array Matrix (Cancer Panel, Illumina) or the Whole Genome gene 
expression BeadChips (HumanRef-8, Illumina) for 16 h at 58 °C. Illumina BeadArray Reader was 
used for scanning the arrays and Illumina BeadScan was used for image acquisition and recovery of 
primary data. 
 
 AFFYMETRIX 
Gene expression profiles of RNA from FFPE samples were obtained using Affymetrix chip HG-
U133 2.0 Plus. 
A total of 5 µg in 50 µL of ssDNA labeled and fragmented with the NuGEN kit were used for each 
sample in the hybridization reaction. The hybridization cocktail was prepared according to the 
manufacturer instructions, using 5 µL of control oligonucleotide B2 (3 nM), 15 µL of  20x 
eukaryotic hybridization controls (bioB, bioC, bioD, cre), 3 µL herring sperm DNA (10 mg/mL), 3 
µL of acetylated BSA (50 mg/mL), 150 µL of 2x hybridization buffer; 30 µL of 100% DMSO and 
44 µL of water to a final volume of 250 µL. Hybridization cocktail was denaturated at 99°C for 5 
min, then placed at 45°Cfor 5 and finally spun at 14,000 rpm for 5 min before loading them on 
arrays. A total of 250 µL of the hybridization cocktails were loaded on arrays after a short 
GeneChip pre-hybridization in 1x hybridization buffer for 10 min in a rotating oven at 45°C and 60 
rpm. Hybridization lasted 18 h in a rotating oven. GeneChips were scanned using the GeneChip 
Scanner 3000 (Affymetrix) using manufacturer’s recommendations. 
 
 
MATERIALS AND METHODS 
  
 
82 
 
3.16  CELL CULTURES 
 
In our study different epithelial cell lines derived from human breast adenocarcinomas were used; 
they were all purchased from the American Type Culture Collection (ATCC): 
 SkBr3 cells were cultured in McCoy’s 5A Medium (Lonza) supplemented with 10% Fetal 
Bovine Serum (FBS). 
 MCF-7 cells and MDA-MB-231 were maintained in Dulbecco’s Modified Eagle’s Medium , 
(DMEM-F12) supplemented with 5% FBS. 
Human fibroblast cell lines of different origin were also used: 
 HTB-125 cell line was purchased from ATCC and derives from human normal breast tissue 
peripheral to an infiltrating ductal carcinoma. It was maintained in ATCC Hybri-Care Medium 
supplemented with 10% FBS and EGF (30 ng/mL). 
 CCL-171 cell line was purchased from ATCC; it derives from human normal lung tissue and 
was cultured in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% FBS. 
 HNDF cell line was purchased from Lonza and derives from human normal derma; it was 
cultured in Fibroblast Basal Medium (FBM) supplemented with Fibroblast Growth Medium-2 
(FGM-2) Bullet kit (Lonza), which consists of 2% FBS, 0.1% Insulin, 0.1% GA 1000 and 0.1% 
FGF. 
 B-CAF MS132 cell line was isolated in our laboratory from a clinical breast tumor and it is α-
SMA positive. It was maintained in FBM supplemented like HNDF cell line. 
 CAF- Red line dyed with PLVX-DS RED-EXPRESS2-N1 VECTOR (CLONOTECH, 
Mountain View, CA, USA). It was maintained in FBM supplemented like HNDF cell line. 
All these cell lines were cultured at 37°C in a 5% carbon dioxide and 95% air humidified 
atmosphere.  
For co-culture experiments MIX medium was used: DMEM F-12+5%FBS + FBM 2%FBS 1:1 
 
 
3.17 TRANSWELL CO-CULTURE SYSTEM 
 
For experiments of Transwell co-cultures were used: MCF-7, SkBr3 and MDA MB231 as epithelial 
cells and HNDF, CCL-171, HTB 125 and B-CAF MS132 as fibroblast cells. 
Co-cultures were performed in the 24-well plates with 6.5mm Transwell® with 0.4 µm Pore 
Polycarbonate Membrane Insert (Costar, Corning Life Science, NY, USA). 
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On the bottom of wells 50 000 epithelial cells were seeded. On top of Transwell chambers only 
10000 fibroblast cells were seeded or 10 000 epithelial cells or 5 000 fibroblast cells +5 000 
epithelial cells (Fig.24). The cells were cultivated for 96 h in serum-free MIX medium. Then the 
conditioned media were collected for cytokines evaluation by Bio- Plex and migration and invasion 
assays while the epithelial cells in the bottom of the wells were collected for RNA extraction. 
 
 
Figure 24: Transwell co-culture model. 
 
 
3.18  MIGRATION/INVASION CO-CULTURE SYSTEMS 
 
This type of assay was performed with MCF-7 and HNDF. 
Only for invasion assay, sterile polycarbonate filters with 8 µm Pore (Costar, Corning Life Science, 
NY, USA) were coated with 60 µl of Matrigel (200 µg/mL) and the membrane were air-dried at 
4°C. The filters were hydrated with 200 µL of serum free media at room temperature for 60 min 
before use. 100 µL o medium containing 38000 MCF-7 cells were added into top Trans chambers, 
and 57000 HNDF were cultured in the lower chambers with 0.5 mL serum-free MIX medium 
(Fig.25). The 24-well plates were incubated in a 5% CO2 humidified incubator at 37°C for 72h. The 
conditioned media were collected to evaluate cytokines concentration by E.L.I.S.A. assays. The 
cells on the upper surface were gently removed with a cotton swab and the filters were fixed with 
ethanol 100% for 30 minutes at -20°C and then washed with distilled water. 
The migrated or invaded cells were stained with sulforhodamine (SRB) for 30 minutes at room 
temperature. After the incubation time, SRB was removed and each well was washed with 
acetic acid 1%. The 24-well plates were dried over night. 
The cells on the lower surface of the filters were quantified with microscope; each test group was 
assayed in triplicate. 
Epithelial cells
Fibroblasts/Epithelial cells
or
Fibroblasts+Epithelial cells
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Figure 25: migration/invasion co-culture model. 
 
 
3.19 3D CO-CULTURED SYSTEM 
 
This assay was performed in 24-well plates, subdivided in ON TOP and EMBEDDED.  
Matrigel (BD BIOSCENCES, San Jose, California) was put at 4° C overnight to thaw. 
Matrigel was prepared on ice in order to have 7 mg/mL diluted in MIX medium. 
The wells were coated with Matrigel: 110 µl for ON TOP and 80 µl for EMBEDDED experiments. 
The plate was incubated for one hour at 37°C. 
During the incubation, MCF-7 and HNDF were trypsinized from monolayer to a single-cell 
suspension and counted with coulter counter. 
For ON TOP assay: 
4 x 103 cells in 100 µl of MIX medium were put in the coated wells and incubated for 30 minutes at 
37°C. During the incubation, MIX serum medium was cooled at 4°C and 1500 µl of MIX medium 
plus 10% of Matrigel were prepared. 100 µl of this medium were placed on top of the cells. 
For EMBEDDED assay: 
4 x 103 cells were mixed with 200 µl of Matrigel (7 mg/mL). This solution was put on coated cells 
and incubated for one hour at 37°C. Then 200 µl of MIX medium were added on top of cells. 
Both assays were incubated for 10 days in a 5% CO2 humidified incubator at 37°C. Later the 
experiment was starved and after 48h the conditioned medium was collected. During the experiment 
some picture were taken under the microscope. 
 
 
Epithelial cells
Fibroblasts
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3.20 MIGRATION ASSAY 
 
Migration assay was performed in the 24-well plates with 6.5mm Transwell® with 8.0µm Pore 
Polycarbonate Membrane Insert (Costar, Corning Life Science, NY, USA).  
 Epithelial cell line SKBR3  and MCF-7 were starved for 96 hours to obtain conditioned 
Medium (C.M.) in different co-culture conditions (see Transwell co-cultures). 
 Under the Transwell insert 1 mL of conditioned medium was added or for the positive control 
medium supplemented with 10% FBS. 
 On the insert 240000 cells were seeded (cells were resuspended in medium without serum). 
 Migration assay was incubated in a 5% CO2 humidified incubator at 37°C for 48h. 
 Then the serum-free medium into each well was removed and wells and filters were washed 
with saline solution. 
 The cells on the upper surface were gently removed with a cotton swab. 
 Then the filters were fixed with ethanol 100% for 30 minutes at -20°C and then washed with 
distilled water. 
 The migrated cells were stained with sulforhodamine (SRB) for 30 minutes at room 
temperature. 
 After the incubation time, SRB was removed and each well was washed with acetic acid 1%. 
 The 24-well plates were dried over night. 
 Finally the filter was quantified under a microscope; each test group was assayed in duplicate. 
 
 
3.21 INVASION ASSAY 
 
Invasion assay was performed in the 24-well plates with 6.5mm Transwell® with 8.0µm Pore 
Polycarbonate Membrane Insert (Corning Life Science) additioned with Matrigel (BD 
BIOSCENCES San Jose, California) 
 Epithelial cell lines SkBr3 and MCF-7 were starved for 96 hours to obtain conditioned Medium’ 
(C.M.) in different co-culture conditions (see Transwell co-cultures). 
 On top of Transwell, the pores were coated with 60 µL of Matrigel (208 µL/mL) and the 
membrane were air dried a RT for 1h. 
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 Under the Transwell insert 1 mL of conditioned medium was added or for the positive control 
medium supplemented with 10% FBS. 
 On the insert 480000 cells were seeded (cells were resuspended in medium without serum) 
 Invasion assay was incubated in a 5% CO2 humidified incubator at 37°C for 48h or for 72h. 
 Then the serum-free medium into each well was removed and wells and filters were washed 
with saline solution. 
 The cells on the upper surface were gently removed with a cotton swab. 
 Then the filters were fixed with ethanol 100% for 30 minutes at -20°C and then washed with 
distilled water. 
 The migrated cells were stained with sulforhodamine (SRB) for 30 minutes at room 
temperature. 
 After the incubation time, SRB was removed and each well was washed with acetic acid 1%. 
 The 24-well plates were dried over night. 
 Finally the filter was quantified under a microscope; each test group was assayed in duplicate. 
3.22 RNA EXTRACTION FROM CULTURED CELLS   
 
 RNA from cultured cells was extracted with Agencourt RNAdvance Cell v2 kit (Beckman 
Coulter), which is based on Solid Phase Reversible Immobilization (SPRI) paramagnetic bead 
technology and is known for its ability to consistently deliver pure nucleic acids of the highest 
quality and yield. This system reliably delivers high RNA recovery and purity without the need 
for filtration or centrifugation. 
 
 
Figure 26: overview of extraction process 
 
 1. The culture medium was removed from the cells as completely as possible.  
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 2. Cultured cells were lysed with Lysis Buffer, digested with Proteinase K and transferred into 
new plate. 
 3. Total RNA was bound to paramagnetic beads. 
 4. The beads were washed from contaminants with Wash Buffer and Ethanol. 
 5. DNase was added to digest genomic DNA. 
 6. RNA was re-bound to beads with Wash Buffer. 
 7. The magnetic beads were washed with 70% Ethanol to remove residual contaminants. 
 8. RNA was eluted in 20μL of RNase-free water from magnetic particles and stored at 80°C. 
 
 
 
 
 
3.23 BIO-PLEX CYTOKINE ASSAY 
 
Initially, for the first co-culture experiments, to investigate the cytokines in the conditioned 
medium, we used a multiplex assay system which permits the simultaneous detection of multiple 
cytokines in a single well of a 96-well microplate. 
  
The Bio- Plex cytokine assay consists of 3 core technologies: 
1. Family of fluorescently dye microspheres (beads) to which biomolecules are bound. 
2. Flow cytometer with two lasers and associated optics to measure biochemical reactions that 
occur on the surface of beads. 
3. High-speed digital signal processor that efficiently manages the fluorescent output. 
 
Principle:  
It is designed in a capture sandwich immunoassay format. An antibody specifically directed against 
the cytokine of interest is covalently coupled to color-coded 5.5µm polystyrene beads. The antibody 
coupled beads are allowed to react with a sample containing an unknown amount of cytokine, or 
with a standard solution containing a known amount of cytokine. 
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A biotinylated detection antibody specific for a different epitope on the cytokine is added to the 
beads. The result is the formation of a sandwich of antibodies around cytokine. The reaction 
mixture is detected by the addition of Strepavidin-phycoerithrin (Strepavidin-PE) which binds to the 
biotinylated detection antibodies. 
 
The constituents of each well are drawn up into the flow-based Bio-Plex suspension array system, 
which identifies and quantifies each specific reaction based on the bead color and fluorescence. The 
magnitude of the reaction is measured using fluorescently labeled reporter molecules associated 
with each target protein. Unknown cytokine concentrations are automatically calculated by Bio-
Plex Manager Software using a standard curve derived from a recombinant cytokine standard. 
 
Procedure: 
We evaluated 2 panels of cytokines for a total of 48:  
1. Bio-Plex PROTM Human Cytokine Standard Group I 27-PLEX. 
2. Bio-Plex PROTM Human Cytokine Standard Group II 21-PLEX. 
 
1. To prepare cytokine standard (Multiplex cytokine standard) 1 tube of the lyophilized cytokine 
standard was reconstituted with 500 µL of MIX MEDIUM (DMEM F-12+5%FBS + FBM 2%FBS 
1:1). After gently mixing by flicking the bottom of the tube 3-5 times, it was incubated on ice for 30 
min. (50,000 pg/mL per cytokine). 
 
2. Cytokine standard curve was prepared in following range 0.2- 3,200 pg/mL by serial dilution in 
MIX MEDIUM. 
 
3. The vacuum filter was calibrated using 96 well plate and fix the Hg level in between 1 and 2. 
 
4. Working bead solution was prepared mixing 5,760 µL of Bio-plex assay buffer and 240 µL of 
25X stock beads in a tube covered with aluminum foil and place in dark. 
 
5. Perform Multiplex Assay procedure: 
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I. 150 µL of Bio-Plex assay buffer were added to pre-wet wells and the buffer was 
removed by vacuum filtration; 
II.  the multiplex bead working solution was vortexed for 15-20 sec at medium speed and 
50 µL was pipetted into each well than vaccum filtered; 
III. 100 µL of Bio-Plex wash buffer were dispensed to each well and were removed by 
vacuum filtration; 
IV. 50 µL standard or sample were added per well; 
V. the filter plate was placed onto a microplate shaker. The shaker speed was regulated to 
1,000 rpm and maintained for 30 sec and reduced to 3,00 rpm for 30 min. 
 
6. Using Detection antibody (50X): 
 
I.          detection antibody diluent A (2940 µL) was pipetted and place in a tube covered with 
foil; 
II.       60 µL of 50X stock detection antibody were added and placed in dark; 
III.        25 µL of detection antibody were added to each well of filter plate (after 3 washes with 
wash buffer); 
IV.       filter plate was  placed onto a shaker after sealing with tape and followed the same rpm 
(1000 rpm for 30 sec. and 3,00 rpm for 30 min.). 
 
7. Using Strepavidin-PE preparation: 
 
I.       5940 µL of Bio-Plex assay buffer were pipetted in a tube covered with foil; 
II.      60 µL of 100X strepavidin-PE were added into the tube and placed in dark; 
III.     50 µL of strepavidin-PE preparation were added to the filter plate after washed 3X with 
Bio-Plex wash buffer; 
IV.      filter plate was  placed onto a shaker and followed the same rpm and incubated for 10 
min at room temperature. 
V.     The buffer was removed by vacuum filtration and 3 washes with 100 µL of Bio-Plex wash 
buffer were done. The buffer was removed by vaccum filtration. 
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VI.     The beads were resuspended in each well with 125 µL of Bio-Plex assay buffer. Filter 
plate was placed onto a shaker at 1000 rpm for 30 sec immediately before to read the 
plate on Bio-Plex system. 
 
The plate was read with the Bio-Plex Reader setting the machine to ready 100 beads/region in a 
volume of 50 µL. After running protocol, Bio-Plex manager was gave standard curve and value of 
each unknown cytokine in samples.  
 
 
3.24 E.L.I.S.A. TEST 
 
Four cytokines were evaluated in the conditioned medium obtained from co-cultures between MCF-
7 with HNDF and MCF-7 with B-CAF Red.  
For the IL-6 and the IL-8 we used Quantikine® High Sensitivity ELISA (R&D Systems, Abingdon, 
UK), and for HGF (Hepatocyte Grow Factor) and SCF (Stem Cell Factor) we used Quantikine® 
ELISA (R&D Systems, Abingdon, UK). 
These kits were performed in according to the manufacturer’s instruction. The assay employs the 
quantitative sandwich enzyme immunoassay technique: a monoclonal antibody specific for each 
cytokine has been pre-coated onto a microplate.  
Standards and samples were pipetted into the wells and cytokines were bounded by the immobilized 
antibody. After washing away any unbound substance, an enzyme-linked polyclonal antibody 
specific for those cytokines was added to the wells. Following a wash to remove any un bound 
antibody-enzyme reagent, a substrate solution was added to the wells. After an incubation period 
(an amplifier solution was added to the wells, for high sensitivity assay) color developed in 
proportion to the amount of cytokines in the initial step. The color development was stopped and 
the intensity of the color was measured with reader plate. 
Reagent preparation: 
Wash buffer: 100 mL of Wash Buffer Concentrate were diluted into 900 mL of de-ionized water. 
Substrate Solution: the lyophilized Substrate was reconstituted with 6 mL of Substrate diluents. 
Amplifier Solution:  the lyophilized Amplifier was reconstituted with 6 mL of Amplifier Diluents. 
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Calibrator Diluent: 10 mL of Calibrator Diluent Concentrate were diluted into 10 mL of de-
ionized or distilled water.  
To quantify the cytokines it was necessary prepare a standard curve. 
Concentration of Standard cytokines: 
IL-6: 5 - 2.5 – 1.25 – 0.625 – 0.312 – 0.156 (pg/mL) in Calibrator Diluent. 
IL-8: 64 – 32 – 16 – 8 – 4 – 2 – 1 (pg/mL) in Calibrator Diluent. 
HGF: 8000 – 4000 – 2000 – 1000 – 500 – 250 – 250 (pg/mL) in Calibrator Diluent. 
SCF: 1000 – 500 – 250 – 125 – 62.5 – 31.2 (pg/mL) in Calibrator Diluent. 
Assay procedure:  
all samples and standard were assayed in duplicated. 
Specific cytokine diluent was added to the wells:  
 assay Diluent RD1W for HGF ELISA. 
 Assay Diluent RD1-1 for SCF ELISA.    
 Assay Diluent RD1-115 for Il-8 ELISA. 
 Assay Diluent RD1-75 for Il-6 ELISA. 
100 µl of Standard and samples were added per well and incubated for 2 hour at room temperature. 
After the incubation period, liquid from the wells was removed inverting the plate, each well was 
filled with 400 µl of Wash Buffer. This step was repeated 5 times. 
200 µl of Cytokine Conjugates were added to all wells and incubated for 2 hour at room 
temperature. 
Then the aspiration and wash steps were repeated. 
50 µl of Substrate Solution were added for Il-6 and Il-8 ELISA and incubated for one hour while 
200 µl of Substrate Solution were added for HGF and SCF ELISA and incubated for 30 minutes. It 
was important protect the plate from light. 
Only for High Sensitivity assay (Il-6 and Il-8) 50 µl of Amplifier Solution were added and incubate 
for 30 minutes. 
Finally 50 µl of Stop Solution were added to each well and determined the optical density of each 
well within 30 minutes, using a microplate reader set to 450 nm for High sensitivity assay and 490 
nm for the other assay. 
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3.25 GREEN FLUORESCENT PROTEIN (GFP) TRANSFECTION 
PROTOCOL FOR VISUALIZING MCF-7 CELL LINE IN 3-D CO-
CULTURE 
 
1. One day before the transfection, MCF-7 were seeded in 3 T25 cell culture flasks in DMEM-
F12 with 5% serum so that the cells will be at ~80% of confluence at the time of 
transfection: two to transfect with the plasmid pEGFP-N1 (Clontech, Palo Alto, CA, USA) 
and one to treat only with Lipofectamine 2000 reagent (Invitrogen, San Diego, CA, USA), 
to act as control. 
2. 4.0 μg GFP-actin vector were diluted in 500 μL of Opti-MEM I reduced serum medium 
(Invitrogen) and then mixed gently. 
 
3. 5 μL of Lipofectamine 2000 was diluted in 500 μL of Opti-MEM and mixed gently.  
 
4. The diluted GFP-actin vector was combined with the diluted Lipofectamine 2000 (total 
volume is 1 mL), mixed and then incubated for 15 minutes at room temperature to allow the 
GFP-actin vector- Lipofectamine 2000 complexes to form. 
 
5. 1 mL GFP-actin vector- Lipofectamine 2000 complexes was added to each T25 flask 
containing cells to treat and then incubated for 5 hours at 37°C; after that the medium was 
removed and replaced with fresh DMEM-F12 with 5% serum.  
 
6. Cells were then cultured for an additional 48 hours before adding 500 µg/mL of Geneticin 
G-418 Sulphato (Gibco, BRL, Gaithersburg, MD), used for the selection and maintenance of 
the GFP-expressing clones.  
 
 
3.26 DATA ANALYSIS AND STATISTICS 
 
3.26.1 ILLUMINA DATA PROCESSING 
Microarray raw data where generated using the Illumina BeadStudio 3.8 software and processed 
using the lumi package (115) of Bioconductor. After quality control, the Robust Spline 
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Normalization was applied and probes with a detection P < 0.01 in at least one sample were 
selected. 
 
3.26.2 METAGENES IDENTIFICATION 
After applying the normalization and filtering procedures described above, the most variable 
probes (IQR>0.5;11334 probes) were selected and subjected to hierarchical clustering using 1-
Pearson correlation as distance metrics and an average linkage method. A correlation threshold of 
r>0.7 was used and only clusters containing at least 7 probes were considered. 
Each probe cluster identified in the above described independent dataset was re-clustered in our 
discovery dataset. Probes correlating 0.7 or less were removed and only clusters with at least 3 
probes left after re-clustering were considered. Probe signals were median scaled and for each 
probes cluster, a metagene was computed as the mean expression of the probes in the cluster.  
To define clusters on Affymetrix data, probesets targeting the genes belonging to each cluster of 
interest were re-clustered on the validation dataset and only those with a correlation > 0.7 were 
retained and used to compute the metagenes values as described. 
 
3.26.3 MOLECULAR SUBTYPES 
Patients were subdivided into three molecular subtypes based on ESR1 and ERBB2 expression 
levels in a way similar to what described in Bianchini et al (116): basal (ESR1-/ERBB2-), 
ERBB2+(ESR1+/-/ERBB2+) and luminal (ESR1+/ERBB2-). The ILMN_15142 and ILMN_28003 
probes for Illumina data and the “205225_at” and “216836_s_at” probesets for Affymetrix data 
were considered as reporters for respectively, ESR1 and ERBB2 gene expression. The threshold 
values to define gene expression positivity were selected according to the strong bimodal 
distribution observed.  
 
3.26.4 CLASS COMPARISON 
The class comparison analysis was performed using a linear modelling approach and empirical 
Bayes methods as implemented in the limma Bioconductor package (R version 2.14). A P<0.05 was 
considered significant if not otherwise specified. 
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3.26.5 SURVIVAL ANALYSIS 
Univariate and multivariate Cox regression, as implemented in the survival Bioconductor package, 
was used to correlate metagenes or other scores with outcome. Metagenes or score values were also 
dichotomized to plot Kaplan-Maier survival curves. Distant Metastasis Free Survival (DMFS) was 
the main endpoint and survival differences were evaluated using the log-rank test. 
 
3.27 ALTERNATIVE CDFS AND NORMALIZATION 
 
Using the altcdenvsf Bioconductor package (version 2.16.0, R version 2.14.1) (Gautier et al, 2004; 
Gentleman et al, 2004), we created an alternative Chip Description File (CDF) where only probes 
unambiguously mapping RefSeq transcripts (hg19, GRCh37) were retained. For genes with 
multiple RefSeq transcripts, the longest isoform was considered (hereafter we refer to this 
alternative CDF as RefSeq_all). 
The affy Bioconductor package (version 1.32.1) (117) was used for data import and MAS5 and 
RMA normalization, while for fRMA we used the package of the same name (version 1.6.0) (118). 
fRMA is based on pre-computed parameters estimated using a large set of CEL files derived from 
the Gene Expression Omnibus repository (119). As parameters need to be re-estimated when using 
an alternative CDF, we carried out our own estimation using the same set of 200 batches of 5 
samples used by the authors, taking advantage of the functions implemented in the frmaTools 
Bioconductor package (version 1.6.0) (120). 
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4. RESULTS AND DISCUSSION 
 
4.1 THE PROGNOSTIC ISSUE 
 
A prognostic marker is defined as a measure able to predict the natural behavior of the disease in 
the absence of any treatment. Prognosis and prognostic markers are generally evaluated in terms 
of time to event as final outcome. In breast cancer pure prognostic studies have been run in node 
negative patients (N-) as they represent low-risk patients where loco-regional treatment alone 
can be considered curative. Prognostic studies on N- patients were available only prior to the 
demonstration of survival benefit of adjuvant treatment in high risk patients. 
 
 Current routinely used prognostic models for node-negative breast cancer that rely on tumor size 
and histologic grade are useful but imperfect. At least two distinct gene expression profiling-
based tests were recently developed that may complement the prognostic prediction for these 
patients. One of these, Mammaprint (Agendia Inc., Amsterdam, Netherlands), was recently 
cleared by the U.S. Food and Drug Administration (FDA) to aid prognostic prediction in node-
negative breast cancer and may become available commercially shortly in this country. This 
assay measures the expression of 70 genes and calculates a prognostic score that can be used to 
categorize patients into good or poor prognostic risk groups (121). Other investigators also 
identified genes that were associated with relapse in node-negative breast cancer; markers were 
selected separately from ER-negative and ER-positive tumors and were combined into a single 
76-gene prognostic signature (VDX2; Veridex, LLC, Warren, NJ). This test was also evaluated 
with two cohorts of patients that received no systemic adjuvant therapy and were not included in 
the development of the test (122). 
Both of these microarray-based assays provide prognostic prediction with moderately 
high precision and seem to have some complementary value to tumor size- and grade-based 
predictions. However, what constitutes a low enough risk to forgo systemic adjuvant 
chemotherapy is influenced not only by the absolute risk of relapse but also by the risk of 
adverse events, the probability of benefit from therapy, and personal preferences. Many patients 
seem to be willing to accept adjuvant chemotherapy for rather small gains in survival. Molecular 
prognostic markers may provide little clinical value for these individuals because no predictive 
test is accurate enough to completely rule out risk of relapse or some potential benefit from 
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adjuvant therapy. However, many other patients are reluctant to accept the toxicities, 
inconvenience, and costs of chemotherapy for a small and uncertain benefit. For these 
individuals, more precise prediction of risk of recurrence and sensitivity to adjuvant therapy with 
genomic tests can assist in making a more informed decision. 
 
4.1.1 PREDICTING DISTANT METASTASES IN NODE NEGATIVE 
PATIENTS 
 
 Many hypotheses have been postulated to explain the nature of the metastatic process, but none 
of them completely accounts for all clinical and biological observations. One important and 
intriguing question is whether the events that modify genes and consequently cellular processes 
required for metastasis are already predetermined in the primary tumor or whether a subset of 
cells gains their metastatic ability in a micro-evolutionary process acquiring additional 
alterations or through selection of the most aggressive clones (123). 
Most gene profiling signatures predicting prognosis in node negative breast cancer link the 
metastatic risk to ER- and/or high proliferating tumors and do not include, with few exceptions, 
the genes reported to be associated to metastases in experimental models. 
This part of study was designed to identify genes linked to the risk of developing metastases in 
node negative patients selected to control the effect of classical prognostic factors on the clinical 
outcome, and all having tumors of the luminal subtype in order to avoid inter-subtype 
confounding effects.  The study included a discovery dataset (profiled at Fondazione IRCCS 
Istituto Nazionale dei Tumori (INT) of Milano) and a validation dataset obtained from the 
literature. 
 The discovery dataset consisted in 123 node negative breast cancer patients developing distant 
metastases within 5 years from surgery (59 patients) and being free of distant metastases (64 
patients) for at least 5 years. In order to control the effect of classical prognostic factors on the 
clinical outcome, patients were selected to obtain similar distributions across metastatic and 
metastasis-free group for age (t-test, P=0.21, N=123) and tumor size (t-test, P=0.64, N=123). In 
keeping with the criticism associated to identification of prognostic signatures on patients not 
subdivided by molecular subtype, we ran all subsequent analyses focusing on the subset of 92 
patients with luminal (ER+/ERBB2-) tumours. To identify such subset in a possibly 
homogeneous way, ER and ERBB2 status were defined based on the strong bimodal expression 
of the corresponding probes (ILMN_15142, ILMN_28003) overcoming this way problems 
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associated to technical variations in ER and ERBB2 determinations over the years. Again, age 
(P=0.211, t-test, N=92) and size (P=0.64, t-test, N=92) were not significantly different between 
the two subgroups of patients developing (N=59) or not (N=64) distant metastases. Data are 
summarized in Table 10.  
 
 
Table 10. Clinico-pathological characteristics of patients. 
 
All analyses were carried out considering expression of metagenes rather than single genes. The 
metagene approach is very effective in simplifying biological interpretation of data, reducing 
multiple testing-associated statistical issues and it allows an easier cross-platform analysis.  
Eight-four clusters of highly correlated genes were first identified by hierarchical clustering and 
79 were validated on the discovery dataset. For each cluster, a metagene was computed as the 
mean expression of all probes after median centring of the signals.  
By class comparison analysis, only the IFN metagene (metagene #42) was found to be 
differentially expressed at statistically significant level (P=0.029, modified t-test, N=92) between 
primaries from patients with or without metastases and it showed a higher expression level in the 
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poor prognosis group. Such metagene (Table11) includes several genes, collectively known as 
interferon-stimulated genes (ISGs), whose products are involved in the host innate immune 
response to viral infections. They are classically upregulated in response to type I interferons, 
IFNα and IFNβ and to lesser extent to Type II, IFNγ in response to viral infection (124). 
 
Illumina probe 
ID 
Gene 
Symbol 
Cytoband Gene Name 
ILMN_1797001 DDX58 9p21.1a DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
ILMN_1729749 HERC5 4q22.1b hect domain and RLD 5 
ILMN_1654639 HERC6 4q22.1b hect domain and RLD 6, transcript variant 4 
ILMN_1835092 HS.125087 
  
ILMN_2058782 IFI27 14q32.13a interferon, alpha-inducible protein 27 
ILMN_1760062 IFI44 1p31.1e interferon-induced protein 44 
ILMN_1723912 IFI44L 1p31.1e interferon-induced protein 44-like 
ILMN_2347798 IFI6 1p35.3b interferon, alpha-inducible protein 6 
ILMN_1781373 IFIH1 2q24.2d interferon induced with helicase C domain 1 
ILMN_1699331 IFIT1 10q23.31b interferon-induced protein with tetratricopeptide repeats 1 
ILMN_1739428 IFIT2 10q23.31b interferon-induced protein with tetratricopeptide repeats 2 
ILMN_2239754 IFIT3 10q23.31b interferon-induced protein with tetratricopeptide repeats 3 
ILMN_2054019 ISG15 1p36.33b ISG15 ubiquitin-like modifier 
ILMN_1662358 MX1 21q22.3a 
myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (mouse) 
ILMN_2410826 OAS1 12q24.13b 2',5'-oligoadenylate synthetase 1, 40/46kDa, transcript variant 3 
ILMN_1672606 OAS1 12q24.13b 2',5'-oligoadenylate synthetase 1, 40/46kDa, transcript variant 1 
ILMN_1736729 OAS2 12q24.13b 2'-5'-oligoadenylate synthetase 2, 69/71kDa , transcript variant 2 
ILMN_2184262 OAS3 12q24.13b 2'-5'-oligoadenylate synthetase 3, 100kDa 
ILMN_1681721 OASL 12q24.31a 2'-5'-oligoadenylate synthetase-like, transcript variant 1 
ILMN_1657871 RSAD2 2p25.2a radical S-adenosyl methionine domain containing 2 
ILMN_1814305 SAMD9 7q21.2b sterile alpha motif domain containing 9 
 
Table 11: Annotation of the IFN cluster. 
 
 
 Among those are IFIT (IFN-induced protein with tetratricopeptide repeats) genes encoding 
IFIT1, IFIT2 and IFIT3, recently shown to form complexes able to bind and inhibit specific viral 
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nucleic acids (125); OAS (2'-5'-oligoadenylate synthetase) genes encoding OAS1, OAS2 and 
OAS3, proteins which cause viral RNA degradation through their ability to synthesize 2',5'-
oligoadenylates; the MX1 (myxovirus resistance 1) gene encoding a protein that physically 
inhibit the assembly of viral particles; genes encoding members of the IFN-regulated ubiquitin 
like protein response (ISGylation; HERC5 and ISG15) which bind numerous protein substrates, 
modulate pleiotropic cellular response and negatively affect viral protein synthesis (126). 
 The relevance for interferon-regulated genes among primary human breast tumors  had already 
been pointed out in gene expression data published since 1999 by Perou and colleagues 
(74;127;128) and a subsequent study, which considered the van’t Veer dataset, reported 
overexpression of a group of ISGs by 40% of breast cancer samples (129). Furthermore higher 
expression of ISGs such as IFI27, IFIT1, IFI35, MX1, GP2 and ISG15 was reported to be 
predictive of  adverse clinical outcome following radiation and chemotherapy (130).  
 To validate the prognostic role of the IFN metagene in luminal tumors and to investigate its role 
in the other breast cancer molecular subtypes we used a combined dataset obtained by pooling 3 
publicly available untreated node negative breast cancer datasets. This allowed us to separately 
test 467 luminal, 104 ERBB2+ and 123 basal tumors, characterized by different clinical outcome 
overcoming the size limits of our discovery dataset concerning non luminal tumors. 
Univariate Cox regression analysis for the IFN metagene (Tab.12) was performed separately 
for each molecular subtype (Fig.30). 
 
IFN cluster 
Gene Probesets 
MX1 202411_at 
IFI27 203153_at 
OAS1 204415_at 
IFIT1 205483_s_at 
IFI6 213797_at 
IFI44L 204439_at 
IFIT3 214453_s_at 
OAS2 202086_at 
ISG15 204747_at 
OAS1 202869_at 
RSAD2 204972_at 
IFI44 205552_s_at 
OAS3 218400_at 
 
Table 12: IFN metagene 
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A slight, but still significant increase in metastatic risk (HR=1.19, 95% CI 1.01-1.41, P=0.04) 
was observed for luminal patients with high IFN metagene expression confirming the results 
found in the discovery dataset. Interestingly, IFN metagene expression was instead associated to 
a 1.69-fold reduction of risk (P=0.0039) in patients whose tumors were classified as ERBB2+, 
whereas only a trend towards protection from distant metastases risk was observed in women 
with basal tumor (HR=0.87; 95% CI 0.68-1.10; P=0.2442). 
 
 
Figure 27: Forest plots showing the HRs of the DMFS univariate Cox regression analyses for the IFN metagene in 
the different molecular subtypes and in the overall population. 
 
The same type of association between IFN metagene expression and clinical outcome was 
observed by Kaplan-Meier analyses defining as IFN metagene positive the 30% of all patients 
with the highest expression values of IFN metagene (Fig. 28). The time function analysis 
confirmed the irrelevant role of IFN metagene expression on outcome in basal tumors (P=0.32, 
log-rank test N=123), its protective role in patients with ERBB2+ tumors (P=0.014, log-rank 
test, N=104) and its association to a shorter DMFS in women with tumors classified as luminal 
(P=0.012, log-rank test, N=457).  
